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Cyclin Dependent Kinase-2 Associated Protein-1 (CDK2AP1) plays an important role in 
cell cycle regulation, by inhibiting CDK2 and by targeting it for proteolysis. It is also known to 
bind the DNA polymerase alpha-primase complex and regulate the initiation step of DNA 
synthesis. Its overexpression has been shown to inhibit growth, reduce invasion and increase 
apoptosis in a number of cancer cell lines. In studies in which mouse embryonic stem cells 
(mESCs) with targeted deletion of the Cdk2ap1 gene were used, Cdk2ap1 was shown to be 
required for epigenetic silencing of Oct4 during differentiation. The goal of this thesis was to 
examine the role of CDK2AP1 in somatic cells (primary human dermal fibroblasts (HDFs)) and 
human embryonic stem cells (hESCs) and specifically assess its impact on proliferation, self-
renewal and differentiation. 
In the first part of this study, using a short-hairpin RNA (shRNA) approach, we 
investigated the effect of CDK2AP1 downregulation in HDFs. Outcomes indicated: (a) reduced 
proliferation, (b) premature senescence, (c) cell cycle alterations, (d) DNA damage, and (e) an 
increase in p53, p21, and the p53-responsive apoptotic genes BAX and PUMA. Simultaneous 
downregulation of p53 and CDK2AP1 in HDFs confirmed that observed phenotype was p53 
dependent.  
In the second part of this study, using a shRNA approach, we investigated the role of 
CDK2AP1 on hESC fate associated with self-renewal and differentiation. We found that 
CDK2AP1 knockdown in hESCs resulted in: (a) reduced self-renewal (b) enhanced 
differentiation (c) cell cycle alterations and (d) increase in p53 expression. Results indicate that 
the knockdown of CDK2AP1 in hESCs enhances differentiation and favors it over a self-renewal 
fate. 
 xiii 
 
Thus, this study has successfully identified novel functions for CDK2AP1, as its 
knockdown has a significant impact on self-renewal, differentiation and senescence.  Results 
obtained from this study could contribute to development of directed differentiation strategies for 
generating uniform populations of differentiated phenotypes from hESCs for clinical 
applications. 
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CHAPTER 1 
 
 
 
Introduction and Review of the Literature 
 
1.1. Human Embryonic Stem Cells 
Embryonic stem cells, the most studied type of pluripotent stem cells, are derived from the 
inner cell mass (ICM) of the preimplantation blastocyst (Smith 2001). The derivation process 
involves the seeding of these cells onto mitotically inactivated mouse embryonic fibroblasts 
(MEF), followed by the expansion of the outgrowth into established human embryonic stem cell 
(hESC) lines. The two main defining characteristics of hESCs are their unlimited capability to 
symmetrically divide and self-renew, and their ability to differentiate into numerous cells derived 
from any of the three germ layers (i.e., ectoderm, mesoderm and endoderm).  
The first successful derivation of hESCs was reported by Thomson and colleagues, wherein 
hESC lines were established by isolating cells from the ICM and plating them onto mitotically 
inactivated MEFs  (Thomson, Itskovitz-Eldor et al. 1998). Subsequently, Reubinoff and 
colleagues were able to establish two diploid hESC lines and propagate them in culture for 
extended periods while maintaining the expression of hESC markers. In addition, the group was 
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able to demonstrate the differentiation potential of hESCs under in vitro conditions. They 
specifically showed that neural progenitors could be isolated from differentiating hESCs and 
could be further induced to differentiate and form mature neurons (Reubinoff, Pera et al. 2000). 
This study provided evidence that hESCs could be utilized as a model to study early human 
embryonic development and also serve as a useful source of cells for applications in 
transplantation therapies. 
The use of hESCs as a source for cell therapeutic approaches (Figure 1) is currently being 
examined for a number of diseases. For instance, one of the earliest studies to document the 
potential for hESCs in treating myocardium diseases demonstrated a great ability of these cells to 
regenerate a damaged heart muscle (Laflamme, Chen et al. 2007). In this study, hESCs were 
successfully differentiated to form cardiomyocytes using a process scaled for clinical production 
and showed normal contractile function along with appropriate responses to cardiac drugs 
(Laflamme, Chen et al. 2007). These cells were then transplanted into animal models of 
myocardial infarction, wherein the cells engrafted and improved the left ventricular function 
(Laflamme, Chen et al. 2007).  
Another promising therapeutic approach that has been explored is the transplantation of 
pulmonary progenitors cells derived from hESCs to regenerate endogenous lung cells damaged 
by injury or disease. In a recent study, researchers utilized a nude mouse model of acute lung 
injury to examine the therapeutic potential of alveolar type II epithelial cells which were derived 
from hESCs (Spitalieri, Quitadamo et al. 2012). HESCs were successfully differentiated in 
culture to alveolar type II pneumocytes, after which the ability of the differentiated cells to 
induce recovery in vivo was examined. Following injection of the committed cells into the 
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mouse models, significant recovery of fibrosis and inflammation was observed when compared 
to non-injected mice. The recovery was demonstrated by restoration of the lung functionality 
measured by blood oxygen saturated levels (Spitalieri, Quitadamo et al. 2012). 
Neurodegenerative diseases are another important target for stem cell-based therapy. 
Parkinson’s disease (PD), which is characterized by the progressive loss of dopaminergic 
neurons, is one that is being initially targeted in the context of stem cell-based therapies. The 
focus in this approach is the functional recovery by replacement of only one cell type 
(dopaminergic neurons), which thus enables the relative ease in testing the true potential of 
hESCs in regenerative medicine (Iyer, Alsayegh et al. 2009). A number of studies that involved 
the transplantation of dopaminergic neurons into the striatum of PD animal models have shown a 
reduction in PD-related motor deficits, increased release of dopamine, and synaptic integration of 
dopaminergic neurons (Perrier, Tabar et al. 2004, Takagi, Takahashi et al. 2005, Yang, Zhang et 
al. 2008). Such studies provided strong evidence towards the potential of hESC-derived 
dopaminergic neuron transplantation as a possible treatment option for PD.  
Although hESCs have great potential, there are few hurdles that need to be solved before 
they can be used in the clinic. In addition to the ethical issues associated with hESC research 
which also initially resulted in restriction of federal funding, safety remains the main challenge. 
It is critical that transplants derived from hESCs contain, as much as possible and almost 
completely, only enriched populations of differentiated cells. The existence of a very small 
number of pluripotent cells thus has the potential to increase the risk for teratoma formation  
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Figure 1: Potential of Pluripotent Stem Cells.  Embryonic stem cells derived from the inner cell mass 
of blastocyst stage embryo differentiate to almost any desired cell type, highlighting their importance 
and potential in regenerative medicine. 
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(Li, Christophersen et al. 2008). Therefore, improved methods are needed to direct 
differentiation into the desired cell types and to minimize the presence of undifferentiated cells. 
Another major issue with the safety of hESC-based cell therapy is the issue of allogeneic 
graft rejection given that the original cell source is not patient-specific. One proposed solution 
has been to generate a large hESC bank from which histocompatible matches could be selected. 
However, even with a close match, transplant recipients may need to use immunosuppressive 
drugs for the rest of their lives, which adds additional risks (Nakajima, Tokunaga et al. 2007, 
Taylor, Bolton et al. 2005). 
1. 2. Cell Cycle Regulation in ESCs 
ESCs are known to have a cell cycle regulation network that is substantially different from 
somatic cells, with cycling time known to be significantly faster when compared with terminally 
differentiated cells. For example, mESCs progress through a single cell cycle in about 8-11 hours 
(White, Dalton 2005), while hESCs progress through the cell cycle in 15-16 hours (Becker, 
Ghule et al. 2006), while many somatic cells progress through the cell cycle  in ~24 hours in cell 
culture (Fluckiger, Marcy et al. 2006).  
The short cell-cycle duration for ESCs results, primarily, from a very short G1 phase that 
lacks a restriction point and a G1 checkpoint. While somatic cells require exogenous growth 
factors to enter the cell cycle, ESCs do not. In addition, in contrast to somatic cells, ESCs are not 
subject to contact inhibition and do not enter quiescence upon withdrawal of growth factors 
(Savatier, Lapillonne et al. 1996, Schratt, Weinhold et al. 2001) . This independence from growth 
factors is most likely caused by the hyperphosphorylation of the retinoblastoma protein (pRb) 
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that in turn, causes continuous activation of the E2F target genes resulting in faster progression 
of the cells into the S phase. Indeed, it was observed that ESCs spend a very short time in the G1 
phase (2 hours in the mouse ESCs) of the cell cycle (Koledova, Kramer et al. 2010). 
In mESCs, all cyclins are expressed at comparable levels throughout the cell cycle, and 
exhibit higher expression when compared with somatic cells (Fujii-Yamamoto, Kim et al. 2005). 
In addition, mESCs do not express CDK inhibitory proteins of the Ink4 and Cip/Kip families 
(Savatier, Lapillonne et al. 1996, Faast, White et al. 2004, Savatier, Huang et al. 1994). For this 
reason, most CDKs are active throughout the cell cycle with the exception of CDK1-Cyclin B 
complex which only becomes active just before the onset of mitosis (Stead, White et al. 2002) 
and CDK4-Cyclin D1 which shows no activity in mESCs (Faast, White et al. 2004). The driving 
force underlying the rapid cell cycle progression in mESCs is the high activity of Cdk2. 
Chemical inhibition of Cdk2 activity prolongs cell-cycle duration and slows the progression of 
mESCs through the G1 phase of the cell cycle. Overexpression of the CDK2 inhibitor p21, for 
example causes similar effects. 
In hESCs, the cell cycle regulation and profile is not overtly different from mESCs, with the 
exception that hESC cell cycle regulators show cell cycle phase-dependent expression 
(Neganova, Zhang et al. 2009). Similar to mESCs, hESCs also exhibit a short G1 phase (Becker, 
Ghule et al. 2006) which is most likely caused by high mRNA levels of CDK4-Cyclin D2 and 
low levels of p21, p27, and p57 (Becker, Stein et al. 2007, Sengupta, Nie et al. 2009). Similar to 
mESCs, members of the Ink4 family are expressed at very low levels in hESCs (Miura, Luo et al. 
2004), and thus contributes to high activity of the CDKs.  In addition, CDK2 was shown to 
display the overall highest kinase activity in hESCs (Neganova, Zhang et al. 2009). Also similar 
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to mESCs, any type of inhibition of CDK2 activity delays the transition from G1 phase to S 
phase of the cell cycle with directed knockdown of CDK2 leading to G1 arrest in hESCs 
(Neganova, Zhang et al. 2009, Filipczyk, Laslett et al. 2007). Taken together, these data indicate 
a crucial role for CDK2 for G1 phase regulation in both mESCs and hESCs.  
1.3. Cell Cycle Regulation in Somatic Cells 
In response to growth factors and/or mitogenic signals, Cyclin D-CDK4/CDK6 complex is 
activated and promotes the phosphorylation of the pRb protein, leading to the progression of 
cells through the G1 phase of the cell cycle (Resnitzky, Reed 1995). E2F dependent induction of 
Cyclin E and CDC25A results in further phosphorylation of the pRb protein and the transition 
from G1 to S phase of the cell cycle. This is mainly controlled by the kinase activity of the 
Cyclin E/CDK2. The Cyclin A/CDK2 complex then controls the progression through S and G2 
phases of the cell cycle. Lastly, Cyclin A and B/CDK1 complexes regulate entry into mitosis and 
control early mitotic events. Somatic cells have a longer doubling time (around 24 hrs) when 
compared to ESCs (Koledova, Kramer et al. 2010) and generally have lower levels of cyclins 
when compared to ESCs. (Fujii-Yamamoto, Kim et al. 2005). In addition, tumor suppressors like 
p21, p27 and p57 are expressed in higher levels in somatic cells than in ESCs (Koledova, Kramer 
et al. 2010).  
1.4. The Relationship Between Cell Cycle and Cell Fate Decisions 
The observed changes in cell cycle regulation and expression of cell cycle regulatory 
proteins during the onset of differentiation in stem cells, indicates a strong link between cell 
cycle regulation and the loss of pluripotency. Additional evidence has also come from studies 
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that examined adult stem cells and the switch they go through when they divide symmetrically or 
asymmetrically. A study that examined the differences in cell cycle between neural progenitors 
that are self-renewing (dividing symmetrically) and neural progenitors that undergo neuron-
generating divisions (asymmetric divisions), revealed that the former cell group have a 
significantly shorter cell cycle (Calegari, Haubensak et al. 2005). Furthermore, the group also 
observed that cells dividing at the basal side of the ventricular zone have a longer G2 phase than 
the self-renewing cells dividing at the ventricular surface (Calegari, Haubensak et al. 2005). 
Interestingly, in another study it was shown that inhibition of CDKs that lengthen the G1 phase 
(but do not arrest in G1) of the cell cycle in whole mouse embryo culture, induced premature 
neurogenesis in those embryos (Calegari, Huttner 2003). It was also shown that overexpression 
of the CDK4-Cyclin D1 complex in neural stem cells resulted in the shortening of the G1 phase 
and was sufficient to promote the switch from neurogenesis to the generation and expansion of 
basal progenitors  (Lange, Huttner et al. 2009).  
Studies in mouse and hESCs have also shown that the connection between cell cycle, self-
renewal and pluripotency exists in pluripotent stem cells. The general phenomenon is that 
prolongation of any of the cell cycle phases and the inhibition of cell cycle progression results in 
the differentiation of ESCs.  An important finding was that the downregulation of CDK2 using a 
chemical inhibitor in hESCs resulted in a delay in the G1-S progression (Filipczyk, Laslett et al. 
2007) while a shRNA mediated knockdown of CDK2 in hESCs resulted in the abrogation of G1-
S phase progression with cells arrested in the G1 phase of the cell cycle (Neganova, Zhang et al. 
2009). In both cases (chemical inhibition and knockdown), differentiation of hESCs was induced 
and measured by reduced expression of OCT4 (Neganova, Zhang et al. 2009, Filipczyk, Laslett 
et al. 2007).  
 9 
 
The above mentioned studies suggest that CDK2 plays a crucial role in the self-renewal and 
differentiation of mouse and hESCs. However, knockout studies that were performed in mice, 
showed that CDK2 is not essential as homozygous Cdk2 knockout mice develop normally in all 
aspects, except in meiosis. These knockout mice demonstrated that Cdk2, although not essential 
for the embryos to develop is however indispensable for meiosis. A more likely explanation is 
that other cell cycle regulation proteins could be compensating for the absence of Cdk2. In 
addition, the state of ESCs in the blastocyst only represents a transient state in early development 
or embryogenesis, fated to differentiate and be under the influence of multiple signals that 
regulate their fate. For that reason, the absence of CDK2 might not affect the cell fate decisions 
in the ESCs of the developing embryo (Koledova, Kramer et al. 2010).  
It is well acknowledged that prolongation of cell cycle in ESCs will most likely lead to the 
differentiation of the cells. Prolongation of the cell cycle due to genotoxic stress in ESCs, was 
shown to result in differentiation as opposed to senescence or apoptosis and interpreted as an 
attempt of ESCs to keep the stem cell pool free of any genetic instability (Lin, Chao et al. 2005). 
This checkpoint that regulates the switch between maintaining self-renewal versus undergoing 
differentiation due to genotoxicity or DNA damage, was attributed to a number of proteins, 
including Ataxia Teleangiectasia Mutated (ATM) and p53 (Inomata, Aoto et al. 2009, Lin, Chao 
et al. 2005). However, it is still not fully clear how exactly self-renewal regulation and DNA 
damage responses are linked with a high possibility that this link might differ from one stem cell 
type to another. A perfect example is that when DNA damage was induced in mESCs, p53 was 
activated leading to the differentiation of the cells by repression of the pluripotency marker 
Nanog by direct binding of p53 to its promoter (Lin, Chao et al. 2005). However, when p53 was 
activated in hESCs by treating with the p53 activator, nutlin, the cells accumulated in the G0/G1 
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phase of the cell cycle that coincided with the elevation of the differentiation markers and a 
decrease in the pluripotency genes through the upregulation of the p53 target gene p21 (Maimets, 
Neganova et al. 2008). 
The link between cell cycle control and pluripotency is strongly supported with the findings 
that show a link between pluripotency markers and major cell cycle regulators. In an interesting 
study, a group aimed to investigate the effect of NANOG overexpression in hESCs (Zhang, 
Neganova et al. 2009). Findings indicated that multiple hESC lines with NANOG overexpressed 
divided significantly faster that the control cells. To test whether this was caused by an increase 
in proliferation or a decrease in apoptosis, Bromodeoxyuridine (BrdU) incorporation assay was 
performed along with apoptosis assay, and it was found that there was no change in rate of 
apoptosis; however, there was a significant increase in BrdU incorporation. In addition, the 
group noticed the absence of the spontaneous and typical signs of differentiation in the NANOG 
overexpressing hESCs, which was a pattern normally exhibited in control hESC cultures.   
By examining the cell cycle profile of the NANOG overexpressing hESCs, it was found that 
the overexpression of NANOG resulted in the acceleration of the progression from G1 to S phase 
of the cell cycle (Zhang, Neganova et al. 2009). Western Blot analysis to examine the levels of 
cell cycle regulatory proteins indicated that the levels of CDK6 and CDC25A were significantly 
increased with NANOG overexpression. Chromatin Immunoprecipitation (ChIP) assay revealed 
that NANOG regulated CDK6 and CDC25A at the transcriptional level. Knockdown studies of 
CDK6 and CDC25A in hESCs revealed that both proteins are important in G1-S progression, 
and their downregulation resulted in a delay in that progression. Furthermore, knockdown of 
CDC25A also resulted in a delay in the G2/M phase progression. Collectively, these data suggest 
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that NANOG, one of the major pluripotency markers, directly controls major cell cycle 
regulatory proteins, which clearly highlights the link between cell cycle regulation and 
pluripotency (Zhang, Neganova et al. 2009).  
Additional studies have also focused on the link between cell cycle regulation and cell fate 
decision. For example, OCT4 and SOX2 were also shown to regulate the expression of key cell 
cycle regulatory proteins like, CDK1, CDC27 and cyclin D1 (Boyer, Lee et al. 2005). Additional 
evidence of a link between the self-renewal machinery and cell cycle regulation has been  
provided by a study (Chavez, Bais et al. 2009) in which researchers carried out an integrated 
analysis of high-throughput data (ChIP-on-chip and RNAi experiments along with promoter 
sequence analysis of putative target genes) and identified a core OCT4 regulatory network in 
hESCs. The results suggest that E2F, a major factor in the G1-S phase transition, may also 
function as a regulatory cofactor of OCT4 at the promoter of OCT4 target genes. In addition, the 
results also revealed that the Origin recognition subunit 1-like protein (ORC1), which is a direct 
target of E2F involved in DNA replication and mitosis, is also part of the core OCT4 regulatory 
network. 
Another important aspect of the relationship between the state of pluripotency and cell cycle 
status, is cell cycle regulation by microRNA’s (miRNAs) (Qi, Yu et al. 2009). For example, 
miRNA 195 and miRNA 372, which are highly expressed in hESCs, regulate two tumor 
suppressor genes, respectively: WEE1, which encodes a negative G2/M kinase modulator of the 
Cyclin B/CDK complex and CDKN1A, which encodes p21, a Cyclin E/CDK cyclin dependent 
kinase inhibitor that regulates the G1/S transition (Figure 2). Together, all these studies 
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demonstrate that pluripotency dictates specific patterns in cell cycle control, that facilitate 
continuous self-renewal of pluripotent cells. 
1.5. Cell Cycle Control and the Induction of Pluripotency 
Since the discovery of reprogramming and the induction of pluripotency in somatic cells, 
many studies have focused on modifying the standard protocol for iPSC generation in order to 
enhance the efficiency of the process and to eliminate the need for any integration or the use of 
exogenous proto-oncogenes. Given that iPSCs resemble ESCs in their cell cycle profile, it was 
intuitive to manipulate cell cycle regulators in somatic cells to alter their cell cycle profile and 
bring closer to that of ESCs, when trying to enhance iPSCs generation. One of the earliest studies 
(Zhao, Yin et al. 2008), utilized a shRNA to downregulate p53 in mouse fibroblasts to examine 
the effect of this knockdown on the efficiency of iPSC generation. Interestingly, the knockdown 
of p53 enhanced the efficiency of reprogramming more than a 100 fold, indicated by the increase 
in the number of alkaline phosphatase (AP) positive colonies. 
Another study demonstrated that p53 deletion enhanced the efficiency of plasmid based 
reprogramming which did not require the integration of exogenous factors in the host cell 
genome (Hong, Takahashi et al. 2009). In the same study, it was revealed that the pathway 
responsible for this enhancement in reprogramming efficiency upon the deletion of p53, is the 
p53-p21 pathway. It was shown that p21 was downregulated in p53 null fibroblasts and resulted 
in the observed improvement in efficiency. Furthermore, it was also suggested that p53 
downregulation may be enhancing reprogramming by promoting immortalization (Mali, Ye et al. 
2008).  
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       Another study that also supports that hypothesis revealed that by knocking down the 
components of the Ink4a/Arf locus (also known as Cdkn2a locus) which encodes the CDK 
inhibitors p16 nk4a and p15 Ink4b and the positive regulator of p53, p19 Arf, reprogramming 
efficiency was significantly increased (Utikal, Polo et al. 2009). In addition, colonies were 
generated with up to three-fold faster kinetics. Interestingly, the reprogramming factor Klf4, was 
also shown to function by suppressing the levels of p53, thus demonstrating its role in enhancing 
efficiency of iPSC generation (Rowland, Bernards et al. 2005).  Furthermore, the reprogramming 
factor Lin28, which is known to positively regulate Cyclins A and B and CDK4 (Xu, Zhang et al. 
2009), was shown to enhance reprogramming efficiency by increasing proliferation (Hanna, 
Saha et al. 2009). Additional evidence of the link between cell cycle regulation and 
reprogramming has been provided by a study that demonstrated an increase in reprogramming 
efficiency by using Rem2 GTPase through two different means. In addition to its effect in 
repressing p53, Rem GTPase also helps increasing the expression and the nuclear localization of 
Cyclin D1, which results in increased progression through cell cycle (Edel, Menchon et al. 
2010). Taken together, all these studies strongly suggest that cell cycle control is a rate-limiting 
step in the process of reprogramming and that reprogramming cannot occur independently 
without a significant change in the cell cycle profile of the starting cell population. 
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Figure 2: Regulation of G1 Phase Progression in Somatic Cells and hESCs. Following 
mitogenic stimulation, Cyclin D1 is synthesized and it stimulates CDK4/6 and together 
they form a complex. Cyclin D-CDK4/6 complex then phosphorylates pRb and that 
releases the E2F which in turn activates proteins like Cyclin E. By forming a complex with 
CDK2, the Cyclin E-CDK2 complex further phosphorylates the pRb releasing more E2F to 
activate S phase related genes. Cyclin E-CDK2 complex also phosphorylates pre-
replication complexes and is important in centrosome duplication. Human ESCs have 
higher levels of cyclins and lower levels of the negative regulators of the CDKs. 
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1.6. Cyclin Dependent Kinase-2 Associated Protein-1 (CDK2AP1): Linking Cell Cycle 
Control and cell Fate 
Human CDK2AP1 is a highly conserved, ubiquitously expressed gene located on 
chromosome 12q24 and is a 115-aa nuclear polypeptide (Tsuji, Duh et al. 1998), while its murine 
equivalent is located on chromosome number 5 and has only 3 amino acids deviations from the 
human CDK2AP1 (Kim, Ohyama et al. 2005). CDK2AP1 is also called Deleted in Oral Cancer-
1 (Doc1) as it was found to be downregulated in about 70% of oral cancers (Shintani, Mihara et 
al. 2001). In vitro studies have revealed that CDK2AP1 mainly functions by regulating the S 
phase of the cell cycle, with studies showing that binding of CDK2AP1 to the 
DNA polymerase alpha /primase complex specifically prevents the initiation step of the DNA 
replication process (Matsuo, Shintani et al. 2000). However, it is still not clear whether this is 
caused by a direct inhibition of the DNA polymerase alpha/primase complex, or by the 
CDK2AP1 downregulation of CDK2, which is responsible for the stimulation of DNA 
replication by phosphorylating the DNA polymerase alpha/primase complex (Matsuo, Shintani et 
al. 2000). 
CDK2AP1 has also been shown to mediate the growth inhibitory effects of the 
Transforming Growth Factor Beta1 (TGF-beta1) (Hu, Hu et al. 2004). In the study reported by 
Hu and colleagues, it was shown that TGF-beta1 induced CDK2AP1 expression 
transcriptionally, which in turn, mediated the growth inhibitory activity of TGF-beta1. The group 
generated HaCaT cells with CDK2AP1 antisense and showed that the reduction in CDK2AP1 
levels resulted in an increase in the levels of CDK2-associated kinase activity, an increase in the 
levels of phosphorylated pRb and increase in proliferation. Additional studies in mouse 
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keratinocytes that were deficient in CDK2AP1 showed that the TGF-beta1 response was 
significantly diminished in those cells when compared to cells expressing normal levels of 
CDK2AP1.  
Numerous studies have demonstrated the association of CDK2AP1 with multiple types of 
cancer. It has primarily been studied in oral cancers, where TGF-beta1 response was shown to be 
decreased. It was reported that there was a decrease in the levels of TGF-beta1 receptor II (TGF-
βRII) that coincides with the transition from carcinoma to metastasis (Meng, Xia et al. 2011), 
with the decrease demonstrated to exhibit a statistically significant correlation with a decrease in 
the expression of CDK2AP1, p21 and p27 (Peng, Shintani et al. 2006). In addition, CDK2AP1 
expression was also found to be decreased in prostate cancer cells. Upon forced overexpression 
of CDK2AP1 in prostate cancer cells, cell cycle arrest and apoptosis were induced along with a 
decrease in cell invasion capacity (Zolochevska, Figueiredo 2009). Furthermore, low levels of 
CDK2AP1 in the gastric tissue of gastric cancer patients, correlated with lower life expectancy, 
while levels of p53 had no significant correlation (Choi, Sohn et al. 2009).  
CDK2AP1 has lately gained importance in the field of stem cell research, with initial studies 
identifying it as one of the stem cell-specific genes that are enriched in both embryonic and adult 
stem cells (Ramalho-Santos, Yoon et al. 2002). It has also been identified as one of many genes 
that are expressed in early stage preimplantation embryos (Sharov, Piao et al. 2003). An 
extensive study analyzed the phenotypic characteristics of a homozygous Cdk2ap1 knockout 
mESCs (Kim, Deshpande et al. 2009). Upon removal of the Leukemia Inhibitory Factor (LIF), 
which is traditionally used to maintain the symmetric division of mESCs, the wild type 
(Cdk2ap1
+/+
) mESCs started showing typical morphological changes that are associated with 
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differentiation. On the other hand, the Cdk2ap1 knockout (Cdk2ap1
-/-
)
 
mESCs appeared normal 
and did not show any signs of differentiation. In addition, although Cdk2ap1
+/+ 
mESCs lost their 
alkaline phosphatase (AP) activity, Cdk2ap1
-/- 
cells were still AP positive. Interestingly, this 
observed phenotype was maintained for up to 20 days in culture. These results indicated that 
differentiation was altered in Cdk2ap1
-/- 
mESCs and that there was increased maintenance of 
self-renewal even under differentiation stimulus, with the reversal of the observed phenotype 
upon introduction of exogenous Cdk2ap1. 
Additionally, the mRNA expression of most of the stem cell-related genes were examined 
by quantitative reverse transcription-PCR using embryoid bodies obtained from Cdk2ap1
+/+
 and 
Cdk2ap1
−/−
 mESCs. Quantitative PCR analysis revealed that levels of Oct4 and Nanog were 
significantly higher in embryoid bodies obtained from Cdk2ap1
−/−
 mESCs when compared to 
Cdk2ap1
+/+
 embryoid bodies. In an attempt to confirm that the findings were caused by the loss 
of Cdk2ap1, stable clones from Cdk2ap1
-/-
mESCs were generated in which Cdk2ap1 was 
ectopically expressed. After differentiating the clones to embryoid bodies and assessing the 
levels of Oct4 and Nanog, it was found that the exogenous Cdk2ap1 caused repression in the 
expression of Oct4 and Nanog in a way similar to Cdk2ap1
+/+
 embryoid bodies. Furthermore, 
qPCR analysis showed a decrease of differentiation markers [Heart and Neural Crest 
Derivatives-expressed protein-1 (Hand1) and homeobox protein Cdx2]  in Cdk2ap1
-/-
embryoid 
bodies compared to Cdk2ap1
+/+
 , and the decrease was reversed in the Cdk2ap1
-/-
 embryoid 
bodies that ectopically expressed Cdk2ap1. These findings support the possibility that Cdk2ap1 
may play an important in regulating stem cell markers during differentiation. 
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Based on previous reports showing that the pRb is hyperphosphorylated when Cdk2ap1 is 
deleted (Shintani, Ohyama et al. 2000), and because pRb was shown to play a role in ES cell 
differentiation (White, Stead et al. 2005) it was intuitive to test whether the loss in differentiation 
capability associated with Cdk2ap1 deletion, was a result of the hyperphosphorylation of pRb. 
Initially, the levels of phosphorylated pRb at serine
788
, which is a site specific for Cdk2 activity, 
were measured and were found to be significantly higher in Cdk2ap1
-/-
 than wild type and 
heterozygote knockout mESCs. This was reversed after the addition of exogenous Cdk2ap1 in 
Cdk2ap1
-/- 
mESCs, and pRb became dephosphorylated. To test whether this observed 
hyperphophorylation of pRb is responsible for the blockade of differentiation, multiple mutant 
forms of pRb were introduced to Cdk2ap1
-/- 
mESCs. The findings revealed that only the S788A 
mutant (mutating the site of Cdk2 induced phosphorylation) could restore differentiation 
capability, clearly demonstrating that the phosphorylation at the serine
788
 is responsible in part 
for the absence of differentiation in Cdk2ap1
-/- 
mESCs (Kim, Deshpande et al. 2009). 
By assessing the effect of the introduction of the pRb mutant S788A on levels of embryonic 
stem cell markers, it was found that Oct4 was significantly reduced independent of LIF removal, 
while Nanog, Sox2 and Rex1 showed more LIF dependence (Kim, Deshpande et al. 2009). 
Interestingly, the differentiation markers Hand1 and Brachyury, showed an increase in their 
levels independent of LIF treatment. On the other hand, introduction of wild type pRb did not 
induce any changes in the expression of pluripotency genes or differentiation markers. 
Collectively, these findings indicate that the loss in differentiation potential of Cdk2ap1
-/- 
mESCs 
is mediated in part through the disruption of pRb regulation through hyperphosphoryaltion of 
serine 788. Overall, this study demonstrated the critical role of Cdk2ap1 in mESC differentiation 
and provided another strong evidence of a link between cell cycle control and cell fate decisions.  
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1.7. CDK2AP1: Its Role in Epigenetics and ESC Differentiation 
During early stages of embryogenesis, embryonic stem cells are subjected to an extensive 
array of signals, like the changes in gene expression at specific stages of embryonic development 
and communications between cells and their surrounding environment (Koledova, Kramer et al. 
2010). An important approach for embryonic stem cells to regulate their response to all these 
signals is through epigenetics. Epigenetic marks, like DNA methylation, histone modifications 
and bivalent chromatin, allow for many genes to be turned on when the appropriate 
developmental time is scheduled. Epigenetic mechanisms are thus essential for embryonic stem 
cells to regulate gene expression without altering nucleotide sequence.  
During embryogenesis, regulation of genes is mediated epigenetically by DNA 
methyltransferases (DNMT) and/or nucleosome remodeling complexes, such as the nucleosome 
remodeling and deacetylase (NuRD) complex. These can modify DNA or histones as a response 
to certain developmental cues, and changes the gene expression profile in an appropriate manner 
(Muller, Leutz 2001, Tong, Hassig et al. 1998). As ESCs differentiate, Oct4 expression is 
downregulated by an increased methylation of its promoter. Alterations of the methylation 
process by DNMT inhibitors and/or alterations of histone deacetylation by histone deactylation 
inhibitors such as Trichostatin, results in failed differentiation of ESCs, which clearly suggest a 
critical role of epigenetics in stem cell fate regulation (Tsuji-Takayama, Inoue et al. 2004). 
Recently, Cdk2ap1 has been linked to epigenetic regulation and embryonic stem cell 
differentiation. Cdk2ap1 was identified to be part of the epigenetic repressor, the NuRD 
complex, and was shown to colocalize with the methyl binding domain-2 (Mbd2) protein subunit 
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of NuRD (Spruijt, Bartels et al. 2010). Gene silencing during the differentiation of mESCs is 
mediated by the NuRD complex and is required for the mESCs to exit pluripotency (Kaji, 
Caballero et al. 2006). Mouse ESCs with MBD3 (a subunit of NuRD complex) deleted, are 
defective in differentiation and display persistent self-renewal (Kaji, Caballero et al. 2006). 
Interestingly, this phenotype exactly matches the one seen in mESCs with Cdk2ap1 removed 
(Deshpande, Dai et al. 2009). In this study (Deshpande, Dai et al. 2009), Cdk2ap1 knockout 
mESCs were generated and their differentiation potential assessed. It was found that lower 
number of EBs could be generated from Cdk2ap1
-/-
mESCs compared to wild type mESCs. More 
interestingly, in day 8 Cdk2ap1
-/- 
Ebs, there was still high expression of the pluripotency gene 
Oct4. Because Oct4 silencing is primarily mediated epigenetically by increased methylation of 
its promoter, methylation-specific PCR (MS-PCR) and bisulfite sequencing was performed on 
day 8 Ebs from Cdk2ap1 knockout and wild cells, which revealed a significant reduction in 
methylation of Oct4 promoter in Cdk2ap1
-/- 
Ebs compared to wild type. The hypermethylation of 
Oct4 promoter following LIF removal was restored in Cdk2ap1
-/- 
after the introduction of 
exogenous Cdk2ap1. Because Cdk2ap1 was reported to be part of the NuRD-MBD3 complex 
(Le Guezennec, Vermeulen et al. 2006) and because of the overlap in the phenotype observed 
when Cdk2ap1 or Mbd3 were deleted in mESCs, co-immunoprecipitation studies were 
performed to determine if Cdk2ap1 interacted with Mdb3. Using bacterially expressed deletion 
mutants of Cdk2ap1 and Mbd3, a sequence of 8 amino acids in the N-terminus of Cdk2ap1 was 
found to be used for the interaction with Mbd3 (Deshpande, Dai et al. 2009).  
ChIP using Cdk2ap1 antibody successfully immunoprecipitated and amplified 
the Oct4 promoter in Ebs derived from WT but not Cdk2ap1
–/–
 mESCs. Because Cdk2ap1 lacks 
a DNA binding domain, it was hypothesized that the presence of Cdk2ap1 at the Oct4 promoter 
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is mediated by its interaction with Mbd3. Following the introduction of an exogenous Cdk2ap1 
in which the 8 amino acid sequence used to interact with Mbd3 was mutated, into Cdk2ap1
–/–
 
mESCs, ChIP data revealed that Cdk2ap1 was no longer present at the Oct4 promoter, compared 
to when the WT form of Cdk2ap1 was used. This study presented valuable information about the 
role of Cdk2ap1 in epigenetic mechanisms during the differentiation of mESCs, and suggested 
that Cdk2ap1 may act as a “Velcro” that holds the different subunits of NuRD together at the 
promoter of Oct4 during mESC differentiation and is indispensable for proper silencing of Oct4. 
  
1.8. Conclusions and Proposed Directions: 
After considering the above mentioned studies which clearly demonstrated the importance 
of Cdk2ap1 in the self-renewal and differentiation of mESCs, our goal was to examine the role 
of CDK2AP1 in the self-renewal and differentiation of human ESCs. We proposed to 
investigate: the (a) effect of CDK2AP1 downregulation on the cell cycle and pluripotency of 
hESCs and (b) the effect of CDK2AP1 knockdown on the growth of human primary fibroblasts. 
a. The effect of CDK2AP1 downregulation on the cell cycle and pluripotency of hESCs: 
Given that the deletion of Cdk2ap1 in mESCs resulted in persistent self-renewal along with 
a decrease in differentiation potential and inability to silence Oct4 upon the induction of 
differentiation (Deshpande, Dai et al. 2009), it would be interesting to test the effects of  
knockdown of CDK2AP1 on the cell cycle and pluripotency of hESCs.  
Experiments under this specific aim attempted to investigate the role of CDK2AP1 in 
hESCs by creating stable cell lines in which CDK2AP1 is knocked down. After establishing the 
cell lines and confirming knockdown, a series of experiments were conducted to examine the 
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effects of this genetic manipulations on cell cycle, self-renewal and differentiation potential of 
the cells.  
b. The effect of CDK2AP1 knockdown on primary human fibroblasts 
Because the loss of CDK2AP1 has been associated with numerous types of cancers, we 
became interested in investigating the effect of CDK2AP1 knockdown on the growth of a normal 
primary human cell line. In addition, primary fibroblasts should serve as another potentially 
useful model to help us further understand the role of CDK2AP1 in human cells and if the role is 
different in embryonic stem cells when compared to differentiated cells.   
In experiments proposed under this specific aim, a stable CDK2AP1 knockdown primary 
fibroblast cell line was generated, after which the effect of the knockdown on cell cycle and cell 
division was examined.  
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CHAPTER 2 
 
 
 
 
Knockdown of CDK2AP1 in Primary Human Fibroblasts Induces p53 Dependent 
Senescence 
 
Abstract 
Cyclin Dependent Kinase-2 Associated Protein-1 (CDK2AP1) is known to be a tumor suppressor 
that plays a role in cell cycle regulation by sequestering monomeric CDK2, and targeting it for 
proteolysis. A reduction of CDK2AP1 expression is known to be a negative prognostic indicator 
in patients with oral squamous cell carcinoma and also associated with increased invasion in 
human gastric cancer tissue. CDK2AP1 overexpression was shown to inhibit growth, reduce 
invasion and increase apoptosis in prostate cancer cell lines. In this study, we investigated the 
effect of CDK2AP1 downregulation in primary human dermal fibroblasts. Using a short-hairpin 
RNA to reduce its expression in primary human fibroblasts, we found that knockdown of 
CDK2AP1 resulted in reduced proliferation and the induction of senescence associated beta-
galactosidase activity. CDK2AP1 knockdown also resulted in a significant reduction in the 
percentage of cells in the S phase and an accumulation of cells in the G1 phase of the cell cycle. 
 24 
 
BrdU proliferation assay revealed a significant reduction in proliferation of the CDK2AP1-
knockdown fibroblasts. Immunocytochemical analysis also revealed that the CDK2AP1 
knockdown fibroblasts significantly increased the percentage of cells that exhibited -H2AX 
foci, which could indicate presence of DNA damage. Quantitative PCR analysis also revealed 
that knockdown of CDK2AP1 resulted in an increase in the mRNA levels of p53, p21, and the 
p53-responsive apoptotic genes BAX and PUMA. In primary human fibroblasts in which p53 and 
CDK2AP1 were simultaneously downregulated, there was: (a) no increase in senescence 
associated beta-galactosidase activity, (b) decrease in the number of cells in the G1-phase and 
increase in number of cells in the S-phase of the cell cycle, and (c) decrease in the mRNA levels 
of p21, BAX and PUMA when compared with CDK2AP1 knockdown only fibroblasts. 
Altogether, our results show knockdown of CDK2AP1 in primary human fibroblasts reduced 
proliferation and induced premature senescence, with the observed phenotype being p53 
dependent. 
 
Introduction 
CDK2AP1 is a cell cycle regulator that controls the G1-S phase transition by negatively 
regulating CDK2 (Shintani, Ohyama et al. 2000). In vitro studies focused on overexpression of 
CDK2AP1 in prostate cancer cell lines results in a decrease in levels of CDK2 and its kinase 
activity, leading to an accumulation of cells in the G1 phase and a reduction in cells that are in 
the S phase of the cell cycle (Zolochevska, Figueiredo 2009). This outcome has been reasoned to 
be mediated by either the  sequestration of monomeric CDK2 or by targeting it for proteolysis. 
Another mechanism by which CDK2AP1 regulates G1-S phase transition, is by directly binding 
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the DNA polymerase/alpha-primase complex and inhibiting the initiation step of DNA 
replication (Matsuo, Shintani et al. 2000). This inhibition may also be a result of CDK2AP1-
mediated reduction in CDK2 activity, which is known to stimulate DNA replication by 
phosphorylating the DNA polymerase-alpha-primase complex.  
CDK2AP1 has also been found to mediate the growth inhibitory effects of TGF-β with 
studies in normal human keratinocytes treated with TGF-β, increased cellular levels of 
CDK2AP1 mRNA and protein (Hu, Hu et al. 2004). Analysis of the results suggests that SMAD 
induced by TGF-β1 binds at the proximal promoter of the CDK2AP1 gene. A significant 
correlative expression of TGF-β receptor II (TGFβRII) and CDK2AP1 has been found in human 
oral squamous cell carcinoma (OSCC) tissues with an observed loss of expression of CDK2AP1 
and p21 (Peng, Shintani et al. 2006). It has also been found that OSCC lines that were resistant to 
TGF-β, were unable to induce SMADs and CDK2AP1, indicating a critical role for CDK2AP1 
in mediating the growth inhibitory effects of TGF-β (Peng, Shintani et al. 2006). The effects of 
overexpressing CDK2AP1 in prostate cancer cell lines, in which it is downregulated were also 
evaluated (Zolochevska, Figueiredo 2009). Overexpression of CDK2AP1 in prostate cancer cell 
lines lead to increased apoptosis, growth arrest and reduced invasion. In gastric cancer, it was 
found that patients who had higher levels of CDK2AP1 in their samples had a better prognosis 
than patients who had low levels of CDK2AP1 (Choi, Sohn et al. 2009).  
In this study, we demonstrate a novel role for CDK2AP1 in primary human fibroblasts, 
with knockdown of CDK2AP1 resulting in reduced proliferation and p53-dependent senescence. 
 
Materials and Methods 
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Generation of Primary Human Fibroblasts Expressing CDK2AP1-specific shRNA and p53-
specific shRNA 
Primary human dermal fibroblasts (HDF) (Coriell Cell Repositories, NJ) were routinely 
maintained in medium containing MEM, 15% FBS, 100 U/ml penicillin and 100 μg/ml 
streptomycin, with subculturing ratios of 1:4 using 0.05% Trypsin solution. All reagents were 
obtained from Invitrogen (Carlsbad, CA) unless otherwise noted. 
We have identified two potent shRNAs targeted to CDK2AP1 mRNA. Multiple shRNAs 
were obtained from commercially available sources (Open Biosystems, PA; Sigma-Aldrich, MO) 
and screened for their effectiveness. Control scrambled sequences were used similarly. To 
identify the shRNA clone that produced the strongest knockdown of CDK2AP1, human 
fibroblasts were transduced with the different shRNA clones using lentiviral vectors, and 
successfully transduced cells were selected by puromycin treatment (3 μg/ml).  Following 6 days 
of selection, antibiotic-resistant cells were harvested and RNA extracted.  QPCR analyses of 
human CDK2AP1specific primers were conducted. In our experiments, one shRNA (labeled as 
shRNA1 henceforth) (Open Biosystems, PA) produced the strongest knockdown and was used in 
subsequent experiments. A second validated CDK2AP1 shRNA (labeled as shRNA2 henceforth) 
(Sigma-Aldrich, MO) that target the 3’-UTR was also used in our studies. In experiments 
involving analysis of the role of p53, expression was downregulated using lentiviral delivery of 
p53-specific shRNA (Addgene, MA, USA), followed by validation of knockdown by qPCR 
analyses.  
RNA Isolation, Real Time Reverse Transcription Polymerase Chain Reaction, and Gene 
Expression Analysis. 
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Table 1: Sequences of Forward and Reverse Primers Used in qPCR Analysis.  
 
Primer Sequence 
GAPDH Forward TTGCCATCAATGACCCCTTCA 
GAPDH Reverse CGCCCCACTTGATTTTGGA 
CDK2AP1 Forward ATGTCTTACAAACCGAACTTGGC 
CDK2AP1 Reverse GCCCGTAGTCACTGAGCAG 
CDKN1A (p21) Forward TGTCCGTCAGAACCCATGC 
CDKN1A (p21) Reverse AAAGTCGAAGTTCCATCGCTC 
Tp53 Forward CAGCACATGACGGAGGTTGT 
Tp53 Reverse TCATCCAAATACTCCACACGC 
PUMA Forward GACCTCAACGCACAGTACGAG 
PUMA Reverse AGGAGTCCCATGATGAGATTGT 
BAX Forward CCCGAGAGGTCTTTTTCCGAG 
BAX Reverse CCAGCCCATGATGGTTCTGAT 
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RNA was isolated using RNeasy kit (Qiagen, CA, USA), according to the manufacturer’s 
protocols and quantified using BioMate3 UV-VIS Spectrophotometer (Thermo Scientific, MA, 
USA). Complimentary DNA (cDNA) was synthesized from 1 g of RNA using cDNA reverse 
transcription kit (Applied Biosystems, CA). Gene expression within different samples was 
analyzed using quantitative real time RT-PCR (QPCR). QPCR was performed in an ABI 
HT7900 system (Applied Biosystems, CA) and the data were acquired using sequence detection 
system software (SDS v2.2.1, Applied Biosystems, CA). Gene expression data (three replicates) 
were acquired and SDS software was used to estimate differential gene expression using CT 
quantification methods. Endogenous Gapdh was used for normalization. Commercially available 
primers for Cdk2ap1were obtained from Origene, MD, while other primers summarized in Table 
1 were obtained from Integrated DNA Technologies, IA. 
Antibodies and Immunocytochemical Analysis  
Under different experimental conditions, human fibroblasts were seeded onto four 
chambered glass slides. Paraformaldehyde (PFA, 4%) in PBS was used for fixation, 
permeabilization for intracellular markers was achieved with 0.2% Triton X-100 in PBS and 
blocked with normal goat serum at room temperature. Fixed cells were incubated with primary 
antibodies: CDK2AP1 (Santa Cruz, CA), Anti-phospho-Histone H2AX (Millipore, CA). Goat 
anti-mouse IgG conjugated to Alexa 488 (for -H2AX staining) and Goat anti-rabbit IgG 
conjugated to Alexa 594 (for CDK2AP1 staining) (Invitrogen, CA,) were used as secondary 
antibodies. The samples were prepared for imaging by overnight exposure to secondary antibody 
at 4
o
C followed by PBS washes, nuclear stain using DAPI (4
’
,6-diamidino-2-phenylindole) and 
finally mounting the slides. Fluorescent images were acquired using a CoolSnap EZ camera 
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(Photometrics, Tucson, AZ) mounted on a Nikon Eclipse TE 2000-S inverted microscope 
(Nikon, Melville, NY) with attached image analysis software. All image settings were controlled 
for uniform acquisition between samples. Specifically, a uniform exposure time was maintained 
for images acquired from experimental samples as well as negative controls for background 
subtraction. Percentages of γ-H2AX positive cells were calculated in multiple fields per sample 
(n=28) by counting the number of cells containing at least 3 foci in their nucleus and dividing by 
the total number of cells in each field of interest. 
Bromodeoxyuridine (BrdU) Proliferation Assay  
For proliferation assays, fibroblasts under different experimental conditions in four-
chambered glass slides were propagated overnight, with subsequent incubation in medium 
containing 20g/ml Bromodeoxyuridine (BrdU) for a period of 2 hrs. Cells were then washed 
with ice cold PBS buffer and fixed with 100% methanol at -20
o
C for 15 min. After fixation, cells 
were washed in cold PBS and permeabilization achieved with 0.2% Triton X-100 in PBS.  For 
DNA denaturation (antigen retrieval), cells were treated with 2N HCl solution for 45 min at 
room temperature. To neutralize the HCl solution, Borate buffer was added for 6 min and cells 
washed. Blocking was achieved by treatment with 3% goat serum in medium for 45 min at room 
temperature. Fixed cells were incubated with Anti-BrdU (Abcam, MA) as the primary antibody. 
Goat anti-rat IgG conjugated to Alexa 594 (Invitrogen, CA) was used as a secondary antibody. 
The samples were prepared for imaging by overnight exposure to secondary antibody at 4
o
C 
followed by PBS washes, nuclear stain using DAPI (4
’
,6-diamidino-2-phenylindole) and finally 
mounting the slides. To determine the percentage of BrdU positive cells, slides were viewed at 
20X magnification and random fields chosen in which total number of cells was determined by 
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counting DAPI, followed by counting the BrdU-positive cells. Triplicate counts of at least 500 
cells each were acquired and the percentage of BrdU positive cells was determined by dividing 
the number of BrdU positive cells by total number of cells.  
Cell Cycle Profile Analysis 
Cells to be analyzed were trypsinized, washed, stained with propidium iodide for 45 min 
at 37
o
C, filtered through a 30 m mesh to eliminate clumps and subjected to cell cycle analysis 
on a Accuri™ C6 Flow Cytometer (BD Biosciences, CA). Data were analyzed using the 
software provided by the manufacturer and samples analyzed in triplicate. 
Senescence Associated β-galactosidase Assay  
Cells to be assayed were seeded in 6-well plates for the senescence-associated b-
galactosidase assay. After 24 h, cells were fixed and stained with X-gal for detection of b-
galactosidase activity using a senescence b-galactosidase staining kit (Cell Signaling, MA). After 
24 h, cells exhibiting positive b-galactosidase activity (turned blue) at pH 6.0 were counted under 
a light microscope.  The percentage of cells exhibiting positive staining was determined in 10 
individual fields of interest.  
Western Blotting 
Cells for analysis were harvested by trypsinization, centrifuged at 1000 rpm and washed 
once with ice-cold PBS buffer. Cells were then lysed using the Total Protein Extraction Kit 
(EMD Millipore, MA) based on protocol provided by the manufacturer. Cell lysates were then 
subjected to Western blot analyses using specific antibodies to various cyclins. Cell lysates were 
prepared from wild type and CDK2AP1 knockdown primary human fibroblasts and analyzed for 
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p53, p21 and -tubulin expression by Western blot using specific antibodies. p53 and p21 
antibodies were obtained from Cell Signaling, MA, while -tubulin antibody was obtained from 
Developmental Studies Hybridoma Bank, IA. Appropriate infrared emitting-conjugated 
secondary antibodies were obtained from Invitrogen, CA. Detection was then carried out using 
the Odyssey Infrared Imaging System (Li-Cor Biosciences, NE).. 
 
Results 
Knockdown of CDK2AP1 in Primary Human Fibroblasts Results in Decreased Cell 
Proliferation and Alters Cell Cycle Profile 
To investigate the effect of CDK2AP1 knockdown on the growth of primary human 
fibroblasts, we used lentiviral delivery of shRNA1 to downregulate CDK2AP1 in primary human 
dermal fibroblasts. CDK2AP1 expression was then examined using qPCR (Figure 3) and 
immunocytochemistry (Figure 4). Based on qPCR analysis, we were able to achieve 90% 
knockdown of CDK2AP1, with statistical analysis indicating significant differences (p <0.05) in 
the expression patterns between primary human fibroblasts transduced with the shRNA1 and 
normal fibroblasts (Figure 3). Additional transduction with a second different CDK2AP1 shRNA 
(shRNA2) resulted in a 96% knockdown of CDK2AP1 (Figure 3). Following the generation of 
CDK2AP1 knockdown primary human fibroblasts, we examined the effect of the knockdown on 
cell proliferation.  Initial analyses conducted in triplicate using hemocytometer counting cells 
indicated that CDK2AP1 knockdown cells exhibited an extremely slow rate of proliferation, 
suggesting that depletion of CDK2AP1inhibited cell proliferation (Figure 5). Subsequent 
analysis using the BrdU proliferation assay indicated that the CDK2AP1 knockdown cells had a 
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significantly lower BrdU incorporation than the wild type fibroblasts (p-value = 0.002) (Figure 
6). Taken together, these results suggest that the knockdown of CDK2AP1 in primary human 
fibroblasts decreases proliferation. 
Cell cycle analysis was then conducted on an equal number of HDFs transduced with an 
empty vector (EV) or HDFs transduced with CDK2AP1 shRNA1 or HDFs transduced with 
CDK2AP1 shRNA2. Analysis demonstrated that the knockdown of CDK2AP1 significantly 
increased cells in the G1 phase of the cell cycle from 78% in the control cells to 94% in 
CDK2AP1 shRNA1 transduced cells (p-value = 0.00026) to 95% in CDK2AP1 shRNA2 
transduced cells (p-value = 0.00022). In addition, knockdown resulted in a significant decrease in 
the percentage of cells in the S-phase of the cell cycle from 8% in the control cells to 1.3% in the 
CDK2AP1-shRNA1 transduced cells (p-value = 0.005) and to 0.6% in the cells transduced 
CDK2AP1-shRNA2  (p-value = 0.004). Under each condition, we also observed few 
necrotic/apoptotic cells present in the sub G0/G1 phase of the cell cycle with 7% in the control 
sample, and 3% and 4% in the CDK2AP1-shRNA1 and CDK2AP1-shRNA2 transduced cells, 
respectively. Taken together, these results indicate that the depletion of CDK2AP1 prevents 
progression from the G1 to the S phase of the cell cycle. 
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Figure 3: CDK2AP1 Gene Expression was Significantly Reduced in HDFs that were 
Transduced with Specific shRNAs. Primary HDFs were transduced with either an empty vector 
(EV) or with a CDK2AP1-shRNA1 or CDK2AP1-shRNA2. After 6 days of puromycin selection 
at 3g/ml, total RNA was extracted and real-time qPCR was used to measure the expression of 
CDK2AP1. The cells that were transduced with CDK2AP1-shRNA1 had 90% reduction in 
CDK2AP1 expression and cells that were transduced with CDK2AP1-shRNA2 had 96% 
reduction, when compared to EV transduced cells. Results are presented together with standard 
deviation from experiments conducted in triplicate. 
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Figure 4: CDK2AP1 Protein is Successfully Downregulated in Cells Transduced with the 
CDK2AP1 Specific shRNA1. Primary HDFs were transduced with either a scrambled shRNA 
(sc-shRNA) (top panel) or with a CDK2AP1-shRNA1 (bottom panel). Following antibiotic 
selection, equal number of cells was seeded onto chamber slides, allowed to propagate for 24 h, 
fixed and stained with CDK2AP1 specific antibody (red) and DAPI (blue-nuclear stain). 
Immunocytochemical staining data showed successful knockdown of CDK2AP1 in primary 
HDFs.  Scale bar represents 100 µm. 
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Figure 5: Knockdown of CDK2AP1 in Primary HDFs Reduces Proliferation. Twenty-five 
thousand cells that were either transduced with an empty vector (EV) or CDK2AP1 shRNA1 
were seeded per well in a 24-well plate. Cells were harvested and counted in triplicates at 2 and 4 
days post seeding (*- p-value < 0.05. Comparisons were made between EV and CDK2AP1 
shRNA1 transduced cells at respective time points).  Results are presented together with standard 
deviation from experiments conducted in triplicate.  
* 
* 
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B.  
 
Figure 6: Knockdown of CDK2AP1 in Primary HDFs Reduces BrdU Incorporation. A. 
Cells transduced with an empty vector (EV) or CDK2AP1-shRNA1 were labeled with 20 µM 
BrdU for 2 h, fixed and stained with a BrdU specific antibody and the percentage of BrdU 
positive cells was calculated. Results are presented together with standard deviation from 
experiments conducted in triplicate. (*-p-value < 0.05). B. Showing representative pictures of the 
quantified immunocytochemistry. BrdU positive cells are shown in red, nuclei were stained with 
DAPI (blue). Scale bar represent 50 m. 
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Figure 7: Knockdown of CDK2AP1 Reduces the Percentage of Cells in the S and G2/M 
Phases and Increases Cells in the G1 Phase of the Cell Cycle. Cells that were transduced with 
empty vector (EV) or with CDK2AP1-shRNA1 or with CDK2AP1-shRNA2 were harvested and 
equal numbers stained with propidium iodide (PI) and analyzed using an Accuri C6 flow 
cytometer. Results are presented together with standard deviation from experiments conducted in 
triplicate (*-p-value < 0.05). 
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Knockdown of CDK2AP1 in Primary Human Fibroblasts Induces Premature Senescence 
During the period of monitoring cell viability, we observed that CDK2AP1 knockdown 
fibroblasts displayed a flattened cellular morphology with progressive cell passage number. To 
investigate whether CDK2AP1 knockdown leads to growth arrest, HDFs transduced with an 
empty vector or HDFs transduced with CDK2AP1-shRNA1 or HDFs transduced with 
CDK2AP1-shRNA2, were plated for senescence associated β-galactosidase assay (SA-β-gal). 
Detection of β-galactosidase activity at pH 6.0 is a known characteristic of senescent cells 
(Dimri, Lee et al. 1995). After 24 h, cells were fixed and stained with X-gal for the detection of 
β-galactosidase activity (Figure 8). 91.7% of HDFs transduced with CDK2AP1-shRNA1 and 
70.8% of CDK2AP1-shRNA2 transduced cells displayed appearance of enlarged blue cells in 
contrast to the control EV transduced cells, which failed to exhibit a detectable blue appearance. 
Therefore, these results suggest that knockdown of CDK2AP1 leads primary human fibroblasts 
to undergo premature senescence. 
Knockdown of CDK2AP1 in Primary Fibroblasts Increases DNA Damage 
To ascertain the reason behind the unexpected reduced proliferation of the CDK2AP1 
knockdown HDFs, we hypothesized that CDK2AP1 knockdown might contribute to a temporary 
abnormal increase in the progression into S-phase of the cell cycle and hence, an uncontrolled 
increase in DNA synthesis. This is based on the reported function of CDK2AP1 as a negative 
regulator of CDK2 and we expected that this could be contributing to errors in DNA synthesis 
and DNA damage (Shintani, Ohyama et al. 2000). 
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Figure 8: Knockdown of CDK2AP1 Altered Morphology and Exhibited Senescence-
Associated β-galactosidase Expression. HDFs that were transduced with an empty vector (EV) 
or CDK2AP1-shRNA1 or CDK2AP1-shRNA2, were seeded and grown in a 6-well plate and 
senescence-associated β-galactosidase assay was performed. CDK2AP1 knockdown fibroblasts 
displayed a significantly higher senescence associated β-galactosidase activity. The percentage 
of cells exhibiting -galactosidase activity is shown at the top of each panel in the right. 
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Figure 9: Knockdown of CDK2AP1 in Primary HDFs Increases -H2AX Signal. A. Primary 
HDFs were either transduced with empty vector (EV), CDK2AP1-shRNA1 or CDK2AP1-
shRNA2. Following antibiotic selection, immunocytochemistry was carried out using a -H2AX 
specific antibody. Percentage of -H2AX was calculated in multiple (n=28) randomly selected 
fields by dividing the number of -H2AX positive cells by total number of cells in the field. 
Results are presented together with standard deviation from multiple fields of view (*-p-value  <  
0.05). B. Example of EV and CDK2AP1-shRNA1 cells stained with -H2AX (green) and the 
nuclear dye, DAPI (blue). Scale bar represents 50 µm.  
EV CDK2AP1-shRNA1
A. 
B. 
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Figure 10: Knockdown of CDK2AP1 in Primary HDFs Leads to Increased Micronuclei 
Formation. Red arrows point to micronuclei, which may be a sign of genetic instability in these 
cells. Scale bar represents 100 μm. 
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To examine this possibility, we measured the number of -H2AX foci in equal numbers 
of CDK2AP1-shRNA1, CDK2AP1-shRNA2 or EV transduced cells that were seeded onto 4-
chamber slides and stained using -H2AX antibody. We found that the knockdown of CDK2AP1 
in HDFs resulted in a significant increase in -H2AX foci with 70% of the CDK2AP1-shRNA1 
HDFs and 84.5% CDK2AP1-shRNA2 cells staining positive, while only 25% of EV cells were 
positive, indicating a potential increase in DNA damage upon CDK2AP1 knockdown (Figure 9). 
Additionally, nuclear staining with DAPI dye indicated that the CDK2AP1-knockdown cells 
exhibited a high number of micronuclei that were surrounding the nuclei of the cells; a 
phenomenon not observed in the control fibroblasts (Figure 10). This observation might be 
considered evidence of genomic instability that the knockdown fibroblasts might have 
experienced before they entered senescence. 
 
Knockdown of CDK2AP1 Increases the Expression of p53, p21 and the Apoptotic Genes 
(BAX and PUMA).  
CDK2AP1 is known to be a member of the Nucleosome Remodeling and Deacetylation 
(NuRD) Complex (Spruijt, Bartels et al. 2010), which is a repressive complex responsible for 
epigenetic regulation of numerous genes. Downregulation of members of the NuRD complex has 
been previously associated with the transcriptional activation of p53 (Kai, Samuel et al. 2010). 
Therefore, we speculated that the knockdown of CDK2AP1 may lead to aberrant epigenetic 
regulation of the p53 gene, leading to abnormal increase in its transcription. QPCR analysis 
(Figure 11) indicated that p53 mRNA levels was increased by 2.3 fold in the CDK2AP1-
shRNA1 HDFs and by 1.89 fold in the HDFs transduced with CDK2AP1-shRNA2 when 
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compared with EV transduced cells.  Similarly, we observed that p21mRNA levels were 
increased by 2.1 fold in the CDK2AP1-shRNA1 cells and by 1.8 fold in the CDK2AP1-shRNA2 
when compared with EV transduced cells. Due to observed decrease in cell viability upon 
CDK2AP1 knockdown, we also decided to examine the expression of candidate p53-responsive 
apoptotic genes, BAX and PUMA. QPCR analysis indicated that BAX mRNA levels was 
increased by 1.5 fold in the CDK2AP1-shRNA1 transduced HDFs and by 2.4 fold in the 
CDK2AP1-shRNA2 when compared with EV transduced cells.  Similarly, we observed that 
PUMA mRNA levels were increased by 2.0 fold in the CDK2AP1-shRNA1 cells and by 3.6 fold 
in cells transduced with CDK2AP1-shRNA2 when compared with EV cells. Western blot 
analysis further confirmed the increase in p53 and p21 protein levels (Figure 12). 
 
Observed Senescence in CDK2AP1Knockdown Primary HDFs is p53 Dependent 
Following CDK2AP1 knockdown, we have observed a ~ 2 fold increase in p53 mRNA 
levels (Figure 11) which was further confirmed by observed increase in p53 protein levels by 
Western blot analysis (Figure 12). The increase in p53 levels may have resulted in the observed 
increase of the transcription of p21, BAX and PUMA (Figure 11). To investigate if the observed 
increase in the levels of transcription of the aforementioned genes in the CDK2AP1 knockdown 
primary HDFs is p53 dependent, we co-transduced primary HDFs with p53 and CDK2AP1 
shRNAs and assayed CDK2AP1, p53, p21, BAX and PUMA expression by qPCR analysis. The 
double-knockdown cells exhibited significantly lowered expression of p53, p21, BAX and PUMA 
(p-value <0.05) when compared with CDK2AP1 only knockdown cells, thus suggesting that the  
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Figure 11: Knockdown of CDK2AP1 in Primary HDFs Increases mRNA Levels of p53, p21, 
BAX and PUMA. To investigate if CDK2AP1 knockdown affects the expression of p53, p21 
and the apoptotic genes BAX and PUMA, total RNA was extracted from cells transduced with 
empty vector (EV), cells transduced with CDK2AP1-shRNA1 and cells transduced with 
CDK2AP1-shRNA2, and levels of p53, p21, BAX and PUMA were measured by qPCR. Results 
are presented together with standard deviation from experiments conducted in triplicate. 
Knockdown of CDK2AP1 using two different shRNAs increased the transcription of p53, p21, 
BAX and PUMA. (p-value < 0.05. Comparisons were made between EV and CDK2AP1-shRNA1 
or EV and CDK2AP1-shRNA2 transduced cells).   
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Figure 12: Knockdown of CDK2AP1 in HDFs Increases p53 and p21 Protein Levels. Whole 
cell lysates were extracted from HDFs transduced with an empty vector (WT) or with CDK2AP1 
shRNA 1 (KD) and analyzed by Western Blot. Knockdown of CDK2AP1 in primary HDFs 
increased protein levels of p53 and p21. 
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observed increase in p21, BAX and PUMA transcription levels in the CDK2AP1 only knockdown 
cells is p53 dependent. 
In experiments conducted with primary HDFs, we found that knockdown of CDK2AP1 
resulted in increased percentage of cells in the G1 phase of the cell cycle and prevents 
progression from the G1 to the S phase of the cell cycle (Figure 7). To test dependence on p53 
expression, we examined the cell cycle profile of primary HDFs that were co-transduced with 
p53 and CDK2AP1 shRNAs. We found that the knockdown of p53 significantly increased the 
percentage of cells in the S phase (p-value = 0.0007) and reduced the cells in G1 phase of the cell 
cycle (p-value = 0.0004) (Figure 14) when compared to CDK2AP1 knockdown only primary 
HDFs (Figure 7). 
To investigate if the simultaneous knockdown of p53 and CDK2AP1 in primary HDFs 
would prevent premature senescence, HDFs transduced with an empty vector or HDFs 
transduced with CDK2AP1 shRNA1 or HDFs transduced with CDK2AP1 shRNA2 and 
exogenous CDK2AP1 (CDK2AP1-shRNA2 + CDK2AP1) or HDFs transduced with CDK2AP1 
shRNA2 and p53 shRNA (CDK2AP1-shRNA2 + shp53) were plated for senescence associated 
β-galactosidase assay (SA-β-gal). After 48 h, cells were fixed and stained with X-gal for the 
detection of β-galactosidase activity (Figure 15). Our results indicate that the fibroblasts that 
were co-transduced with the CDK2AP1 and p53 shRNAs did not enter premature senescence 
and had extremely low β-galactosidase activity.  Taken together, these results indicate that 
downregulation of CDK2AP1 increases p53 expression which pushes primary human fibroblasts 
to enter a p53 dependent premature senescence.  
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Figure 13: Knockdown of p53 in Primary HDFs Prevents the CDK2AP1-knockdown 
Induced Increase in p21, BAX or PUMA gene expression. Primary HDFs were transduced 
with empty vector (EV), CDK2AP1 shRNA or co-transduced with CDK2AP1 and p53 shRNAs. 
The gene expression of CDK2AP1, p21, p53, BAX and PUMA was analyzed in those cells by 
qPCR. We found that down regulating p53 with CDK2AP1 prevented the CDK2AP1-
knockdown induced increase in p21, p53, BAX and PUMA levels (p <0.05. Comparisons were 
made between EV and CDK2AP1-shRNA or CDK2AP1-shRNA and CDK2AP1-shRNA + 
shp53 transduced cells for each gene analyzed). Results are presented together with standard 
deviation from experiments conducted in triplicate. 
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Figure 14: Simultaneous Knockdown of CDK2AP1 and p53 Results in Higher Percentage 
of Cells in the S Phase. Primary HDFs were co-transduced with CDK2AP1 and p53 shRNAs, 
stained with propidium iodide and analyzed by flow cytometry to examine their cell cycle 
profile. Knockdown of CDK2AP1 in primary HDFs reduces the percentage of cells in the S and 
G2/M phases and increases cells in the G1phase of the cell cycle. When p53 is simultaneously 
downregulated with CDK2AP1, it results in an increase in the percentage of cells in the S-phase 
and reduction in the percentage of cells in the G1-phase of the cell cycle. Results are presented 
together with standard deviation from experiments conducted in triplicate. Cell cycle profiles of 
EV and CDK2AP1-shRNA1 transduced cells from figure 7 are also presented here to facilitate 
comparison. 
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Figure 15:  Simultaneous Knockdown of CDK2AP1 and p53 Prevents Premature 
Senescence.  Primary HDFs that were transduced with an empty vector (EV), CDK2AP1 
shRNA1, CDK2AP1 shRNA2 and exogenous CDK2AP1 (CDK2AP1-shRNA2+ CDK2AP1) or 
CDK2AP1 shRNA2 and p53 shRNA (CDK2AP1-shRNA2+shp53) were seeded onto a 6-well 
plate and senescence-associated β-galactosidase assay was performed. CDK2AP1 knockdown 
fibroblasts displayed a significantly higher senescence associated β-galactosidase activity, while 
the simultaneous knockdown of CDK2AP1 and p53 results in significantly reduced senescence 
associated β-galactosidase activity. The percentage of cells exhibiting -galactosidase activity is 
shown at the top of each panel. 
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Discussion and Conclusions 
The function of CDK2AP1 as initially assessed in multiple cancer cell lines indicates its 
role in regulation of apoptosis, proliferation and invasion (Zolochevska, Figueiredo 2009). 
Although the primary function of CDK2AP1 as a cell cycle regulator that controls the G1-S 
phase transition by negatively regulating CDK2 has been ascertained (Shintani, Ohyama et al. 
2000), its role in primary human fibroblasts has not been studied.   To investigate the function of 
CDK2AP1 in primary human fibroblasts, we knocked down CDK2AP1 expression in primary 
human dermal fibroblasts (HDFs) using short hairpin RNA. Using a lentiviral approach, we were 
able to downregulate CDK2AP1 by ~90%. Following knockdown of CDK2AP1 in primary 
HDFs, we observed a distinct reduction in the proliferation potential of these cells, with the cells 
exhibiting morphological changes as well. The CDK2AP1 knockdown HDFs appeared enlarged, 
flat and more spread out. Given that reduced proliferation and flattened morphologies is a sign of 
premature senescence in primary somatic cells, we decided to examine the CDK2AP1 
knockdown HDFs for senescence associated β-galactosidase activity. Results indicated that 
CDK2AP1 knockdown HDFs displayed a significantly higher senescence associated β-
galactosidase activity. 
Given that CDK2AP1 is a known inhibitor of CDK2 and has also been reported to 
associate with the DNA polymerase/alpha primase complex (Shintani, Ohyama et al. 2000, 
Matsuo, Shintani et al. 2000), we expected that following its knockdown, the inhibition might 
have been alleviated allowing abnormal increase in DNA synthesis, which could lead to DNA 
damage. Using immunocytochemical analysis, we examined the CDK2AP1 knockdown cells for 
levels of -H2AX foci, a known indicator of DNA damage. Our results indicated that the 
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CDK2AP1 knockdown HDFs had significantly higher number of cells that were -H2AX 
positive (having more than three H2AX foci in each cell). Additionally, we observed that the 
CDK2AP1 knockdown HDFs had a high number of micronuclei that were surrounding the nuclei 
when examined by DAPI staining (Figure 10). These findings might be considered evidence of 
genomic instability that the CDK2AP1 knockdown HDFs might have experienced before they 
entered senescence. In addition, the suspected initial uncontrolled increase in DNA synthesis due 
to CDK2AP1 knockdown, might have been sensed as oncogenic stress by the cell, leading to the 
activation of the tumor suppressor p53 (Sakaguchi, Herrera et al. 1998)(Haigis,K.M., et al. 
2011). Indeed, we have found p53 protein levels to be increased following CDK2AP1 
knockdown. Also, following CDK2AP1 knockdown, CDK2 activity might have been increased 
causing increased phosphorylation of the retinoblastoma protein (pRb) leading to aberrant 
upregulation of the oncogene, E2F. This may have led to a p16 mediated degradation of the 
negative regulator of p53, Mouse Double Minute-2 (MDM2) (Sherr 2001) and p53 stabilization, 
which in turn could have resulted in senescence. Additionally, our results also demonstrate an 
increase in p21and the candidate p53-responsive apoptotic genes BAX and PUMA expression in 
the CDK2AP1 knockdown HDFs. 
CDK2AP1 has also been reported to be a member of the epigenetically repressive 
complex, NuRD (Spruijt, Bartels et al. 2010).  A previous study demonstrated that disruption of 
a member of the NuRD complex leads to an increase in p53 levels (Kai, Samuel et al. 2010). In 
our studies, we have observed an increase in p53 transcription following CDK2AP1 knockdown, 
which could be a result of the disruption of the NuRD complex. Deletion of CDK2AP1 has been 
previously reported to alter epigenetic marks on genes that are regulated by the NuRD complex, 
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and these genes could not be silenced in the absence of CDK2AP1 due to disrupted localization 
of NuRD (Deshpande, Dai et al. 2009). Therefore, it is possible that following CDK2AP1 
knockdown, the NuRD complex could not localize properly to regulate p53 transcription, which 
could thus have caused the observed increased levels of p53 in the CDK2AP1 knockdown HDFs.  
Given the observed increase in p53 levels upon CDK2AP1 knockdown, we decided to 
extensively examine the dependence on p53 in the CDK2AP1 knockdown HDFs. We observed 
that when p53 and CDK2AP1 were simultaneously downregulated in primary HDFs, the cells 
did not enter senescence based on reduced senescence associated β-galactosidase activity. The 
simultaneous knockdown of p53 and CDK2AP1 also led to reduction of accumulation of cells in 
the G1 phase and increased cells in the S phase of the cell cycle. qPCR analysis further 
demonstrated that knockdown of p53 in HDFs prevents the CDK2AP1 knockdown induced 
increase in p21, BAX or PUMA gene expression. Together, these results lead us to conclude that 
the CDK2AP1knockdown induced senescence in primary HDFs is p53 dependent.  
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CHAPTER 3 
 
 
 
 
Knockdown of CDK2AP1 in Human Embryonic Stem Cells Reduces the Threshold of 
Differentiation 
 
Abstract 
Recent studies have suggested a role for the Cyclin Dependent Kinase-2 Associated 
Protein 1 (CDK2AP1) in stem cell differentiation and self-renewal. In studies with mouse 
embryonic stem cells (mESCs) derived from generated mice embryos with targeted deletion of 
the Cdk2ap1 gene, CDK2AP1 was shown to be required for epigenetic silencing of Oct4 during 
differentiation, with deletion resulting in persistent self-renewal and reduced differentiation 
potential. Differentiation capacity was restored in these cells following the introduction of a non-
phosphorylatible form of the retinoblastoma protein (pRb) or exogenous Cdk2ap1.  In this study, 
we investigated the role of CDK2AP1 in human embryonic stem cells (hESCs). Using a shRNA 
to reduce its expression in hESCs, we found that CDK2AP1 knockdown resulted in a significant 
reduction in the expression of the pluripotency genes, OCT4 and NANOG. We also found that 
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CDK2AP1 knockdown increased the number of embryoid bodies (EBs) formed when 
differentiation was induced. In addition, the generated EBs had significantly higher expression of 
markers of all three germ layers, indicating that CDK2AP1 knockdown enhanced differentiation. 
CDK2AP1 knockdown also resulted in reduced proliferation and reduced the percentage of cells 
in the S phase and increased cells in the G2/M phase of the cell cycle. Further investigation 
revealed that a higher level of p53 protein was present in the CDK2AP1 knockdown hESCs. In 
hESCs in which p53 and CDK2AP1 were simultaneously downregulated, OCT4 and NANOG 
expression was not affected and percentage of cells in the S phase of the cell cycle was not 
reduced. Taken together, our results indicate that the knockdown of CDK2AP1 in hESCs results 
in increased p53 and enhances differentiation and favors it over a self-renewal fate. 
 
Introduction 
Human CDK2AP1 is a highly conserved, ubiquitously expressed gene located on 
chromosome 12q24 and is a 115-aa nuclear polypeptide (Tsuji, Duh et al. 1998). The murine 
homolog of CDK2AP1 is located on chromosome number 5 and has only 3 amino acids 
deviations from the human protein (Kim, Ohyama et al. 2005). CDK2AP1 is also called Deleted 
in Oral Cancer-1 (Doc1) as it was found to be downregulated in about 70% of oral cancers 
(Shintani, Mihara et al. 2001). In vitro studies have revealed that CDK2AP1 mainly functions by 
regulating the S phase of the cell cycle, with studies showing that binding of CDK2AP1 to the 
DNA polymerase alpha/primase complex specifically prevents the initiation step of the DNA 
replication process (Matsuo, Shintani et al. 2000). It has also been shown to regulate G1/S phase 
progression by inhibiting CDK2 and targeting it for proteolysis (Shintani, Ohyama et al. 2000).  
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CDK2AP1 has lately gained importance in the field of stem cell research, with initial 
studies identifying it as one of the stem cell-specific genes that are enriched in both embryonic 
and adult stem cells (Ramalho-Santos, Yoon et al. 2002). It has also been identified as one of 
many genes that are expressed in early stage preimplantation embryos (Sharov, Piao et al. 2003). 
In studies conducted with homozygous Cdk2ap1 knockout mESCs, the effects of LIF (leukemia 
Inhibitory Factor) removal on the Cdk2ap1 knockout and wild type cells were examined 
(Deshpande, Dai et al. 2009). Upon the removal of LIF, Cdk2ap1
+/+
 mESCs showed signs of 
differentiation and reduced the expression of the pluripotency gene Oct4, whereas the Cdk2ap1
-/-
 
mESCs maintained their expression of Oct4 and did not display any signs of differentiation 
(Deshpande, Dai et al. 2009). Further investigation revealed that deletion of Cdk2ap1 in mESCs 
prevented methylation of Oct4 promoter which resulted in the maintenance of its expression 
even in 8 day old embryoid bodies. In  a subsequent study, deletion of Cdk2ap1 in mESCs 
prevented differentiation and resulted in persistent self-renewal, attributed to hyper-
phosphorylation of the retinoblastoma protein (pRb). Differentiation capacity in the Cdk2ap1
-/-
 
mESCs was restored upon the introduction of a mutant non-phosphorylatable form of pRb or 
exogenous Cdk2ap1 (Kim, Deshpande et al. 2009). Taken together, these studies suggest that 
deletion of Cdk2ap1 in mESCs results in increased self-renewal and a decrease in differentiation. 
In this study, we have uncovered a novel function for CDK2AP1 in the self-renewal and 
pluripotency of human embryonic stem cells. Knockdown of CDK2AP1 in hESCs most likely 
results in increased p53 and enhances differentiation potential and favors it over self-renewal.   
Materials and Methods 
Generation of Inactivated Feeder Layers and Conditioned Medium 
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Mouse embryonic fibroblasts (MEFs) were isolated from embryos derived from 13.5 
days pregnant CF1 mice and maintained in MEF-medium containing Dulbecco’s modified 
Eagle’s medium (DMEM) with 4.5 g/L glucose, 2 mM L-glutamine, 1% penicillin/streptomycin, 
and 10% fetal bovine serum.  MEF-conditioned medium (CM) was generated by seeding 1x 10
6
  
mitotically inactivated MEFs on10 cm dishes in 10 ml MEF- medium. The following day, MEF-
medium was replaced with 10 ml of human embryonic stem cell (hESC)medium containing 
DMEM/F-12, 20% knockout serum, 2 mM L-glutamine, 1%  nonessential amino acids, 50 U/mL 
penicillin, 50 μg/mL streptomycin, 0.1 mM beta-mercaptoethanol MEF-CM medium was 
collected and replaced with fresh medium every day, with collected medium filtered and either 
used immediately to propagate hESCs or stored at -20
o
C. 4ng/ml bFGF was added to MEF-CM 
before use for propagating hESCs. All reagents were obtained from Invitrogen (Carlsbad, CA) 
unless otherwise noted. 
Propagation of Human Pluripotent Stem Cells 
Karyotypically normal diploid hESC (H9, http://stemcells.nih.gov) and a hiPSC line 
(WiCell Research Institute, Madison, WI) were routinely passaged on MEFs in 35-mm dishes. A 
rapidly dividing, karyotypically aneuploid cell line BG01v (ATCC, VA) hESC was also 
routinely passaged on MEFs in 35-mm dishes.  H9 and BG01v hESCs were passaged as colonies 
by enzymatically methods every 3–4 days at subculturing ratios of 1:4 and maintained in hESC-
medium. For use in our experiments, both H9 and BG01v hESCs were transferred onto 
Matrigel
TM
 (BD Biosciences, CA) coated cell culture plates and propagated in MEF-CM. 
Generation of hESCs Expressing CDK2AP1-Specific shRNA and p53-Specific shRNA  
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We have identified two potent shRNAs targeted to CDK2AP1 mRNA.  Multiple shRNAs 
were obtained from commercially available sources (Open Biosystems, PA; Sigma-Aldrich, MO) 
and screened for their effectiveness. Control scrambled sequences were used similarly. To 
identify the shRNA clone that produced the strongest knockdown of CDK2AP1, hESCs were 
transduced with the different shRNA clones using lentiviral vectors and successfully transduced 
cells were selected by puromycin treatment (1 μg/ml). Following 6 days of selection, antibiotic-
resistant colonies were harvested and RNA extracted. QPCR analyses using human CDK2AP1 
specific primers were conducted. In our experiments, one shRNA (labeled as shRNA1 
henceforth) (Open Biosystems, PA) produced the strongest knockdown and was used in 
subsequent experiments. For rescue experiments, validated CDK2AP1 shRNA (labeled as 
shRNA2 henceforth) (Sigma-Aldrich, MO) that target the 3’-UTR was used. In experiments 
involving analysis of the role of p53, expression was downregulated using lentiviral delivery of 
p53-specific shRNA (Addgene, MA, USA), followed by validation of knockdown by qPCR 
analyses.  
In vitro Differentiation of hESCs and Histopathology of hESC-derived Embryoid Bodies  
To generate embryoid bodies (EBs), hESCs were dissociated using collagenase and 
resuspended in growth medium devoid of bFGF. EB formation was facilitated using suspension 
culture by a hanging drop method, where cells at a density of 25,000 cells/mL were suspended 
from a Petri dish lid in 20 L droplets. After 2 days, the EBs were transferred to agarose plates at 
a density of 25–30 EBs/10 mL to facilitate further differentiation with media changes every 3–4 
days, for a total differentiation duration of 18 days. EBs were prepared for histopathological 
analysis by fixation in 3.7% PFA in 1.5ml microfuge tubes at approximately 15-25 EBs per tube. 
Once fixed overnight, EBs were rinsed with PBS to remove PFA, resuspended in 200 μl melted 
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4% low melting point agarose (Sigma Aldrich, MO, USA) at 42°C and incubated for 2 hours to 
allow settling. Final pelleting and agarose solidification was performed with brief room 
temperature centrifugation at 500g. Agarose-embedded samples were processed for paraffin 
sectioning in a Leica TP1020 tissue processor. Hematoxylin and eosin (H&E) staining was 
performed on microscope slide-mounted 5μm sections in a Leica Autostainer XL workstation. 
Images were acquired using a Nikon TS-100 microscope using the default imaging parameters. 
H&E staining and histopathological analysis was conducted in collaboration with Dr. Steven 
Sheridan at Center for Human Genetic Research, Massachusetts General Hospital, Harvard 
Medical School. 
RNA Isolation, Real Time Reverse Transcription Polymerase Chain Reaction, and Gene 
Expression Analysis 
RNA was isolated from hESCs and EBs under different conditions using RNeasy kit 
(Qiagen, CA, USA), according to the manufacturer’s protocols and quantified using BioMate3 
UV-VIS Spectrophotometer (Thermo Scientific, MA, USA). cDNA was synthesized from 1 g 
of RNA using cDNA reverse transcription kit (Applied Biosystems, CA). Gene expression 
within different samples was analyzed using quantitative real time RT-PCR (QPCR). QPCR was 
performed in an ABI HT7900 system (Applied Biosystems, CA) and the data were acquired 
using sequence detection system software (SDS v2.2.1, Applied Biosystems, CA). Gene 
expression data (three replicates) were acquired and SDS software was used to estimate 
differential gene expression using CT quantification methods. Endogenous GAPDH was used 
for normalization. Commercially available primers for CDK2AP1 and OCT4 were obtained from 
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Origene, MD, while other primers summarized in Table 1 were obtained from Integrated DNA 
Technologies, IA. 
Antibodies and Immunocytochemical Analysis 
Under different experimental conditions, hESCs were seeded onto four chambered glass slides. 
Paraformaldehyde (PFA, 4%) in PBS was used for fixation, permeabilization for intracellular 
markers was achieved with 0.2% Triton X-100 in PBS and blocked with normal goat serum. 
Fixed cells were incubated with primary antibodies: CDK2AP1 (Santa Cruz, CA, USA) and 
Anti-Phospho-Histone-3 (Cell Signaling, MA, USA). Goat anti-rabbit IgG conjugated to Alexa 
594 (Invitrogen, CA,) was used as a secondary antibody. Fluorescent images were acquired using 
a Cool- Snap EZ camera (Photometrics, Tucson, AZ) mounted on a Nikon Eclipse TE 2000-S 
inverted microscope (Nikon, Melville, NY) with attached image analysis software. All image 
settings were controlled for uniform acquisition between samples. Specifically, uniform exposure 
time was maintained for images acquired from experimental samples as well as negative controls 
for background subtraction. For experiments involving determination of mitotic index based on 
phospho-histone 3 staining, random fields were selected and counting was performed in triplicate 
by counting around 500 cells during each analyses. Mitotic index was calculated by dividing the 
number of phospho-histone 3 positive cells, over the total number of cells. 
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Table 2: Sequences of Forward and Reverse Primers Used in qPCR Analysis. 
  
Primer Sequence 
GAPDH Forward TTGCCATCAATGACCCCTTCA 
GAPDH Reverse CGCCCCACTTGATTTTGGA 
CDK2AP1 Forward ATGTCTTACAAACCGAACTTGGC 
CDK2AP1 Reverse GCCCGTAGTCACTGAGCAG 
SOX1 Forward ATGCACCGCTACGACATGG 
SOX1 Reverse CTCATGTAGCCCTGCGAGTTG 
NESTIN Forward CTGCTACCCTTGAGACACCTG 
NESTIN Reverse GGGCTCTGATCTCTGCATCTAC 
T Brachyury Forward TGCTTCCCTGAGACCCAGTT 
T Brachyury Reverse GATCACTTCTTTCCTTTGCATCAAG 
IGF2 Forward TCCTCCCTGGACAATCAGAC 
IGF2 Reverse AGAAGCACCAGCATCGACTT 
AFP Forward CTTTGGGCTGCTCGCTATGA 
AFP Reverse GCATGTTGATTTAACAAGCTGCT 
GATA4 Forward GTGTCCCAGACGTTCTCAGTC 
GATA4 Reverse GGGAGACGCATAGCCTTGT 
CDKN1A (p21) Forward TGTCCGTCAGAACCCATGC 
CDKN1A (p21) Reverse AAAGTCGAAGTTCCATCGCTC 
Tp53 Forward CAGCACATGACGGAGGTTGT 
Tp53 Reverse TCATCCAAATACTCCACACGC 
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Western Blot Analysis  
Cells for analysis were harvested by trypsinization, centrifuged at 1000 rpm and washed 
once with ice-cold PBS buffer. Cells were then lysed using the Total Protein Extraction Kit 
(EMD Millipore, MA)) based on protocol provided by the manufacturer. Cell lysates were then 
subjected to Western blot analyses using specific antibodies to various cyclins. Cell lysates were 
prepared from wild type and CDK2AP1 knockdown H9 hESCs and analyzed for CDK2AP1, 
OCT4, NANOG, p53, Cyclin A1 expression by Western blot using specific antibodies. The 
CDK2AP1, OCT4, NANOG and Cyclin A1 antibodies were obtained from Santa Cruz, CA, 
USA, while p53 antibody was obtained from Cell Signaling, MA, USA. Appropriate infrared 
emitting-conjugated secondary antibodies were obtained from Invitrogen, CA. Detection was 
then carried out using the Odyssey Infrared Imaging System (Li-Cor Biosciences, NE). The 
quantitative analysis of the Western Blot bands was carried out using the ImageJ software 
(Schneider, Rasband et al. 2012).  
Cell Cycle Profile Analysis 
Cells to be analyzed were trypsinized, washed, stained with propidium iodide for 45 min 
at 37
o
C, filtered through a 30 m mesh to eliminate clumps and subjected to cell cycle analysis 
on a Accuri™ C6 Flow Cytometer (BD Biosciences, CA). Data were analyzed using the 
software provided by the manufacturer and samples analyzed in triplicate. 
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Results 
 
Knockdown of CDK2AP1 in hESCs Reduces OCT4 and NANOG Expression 
To investigate the effect of CDK2AP1 knockdown on the expression of the core 
pluripotent genes OCT4 and NANOG, we used lentiviral delivery of shRNA1 to downregulate 
CDK2AP1 in H9 hESC line. The CDK2AP1 shRNA clones tested utilize the U6 promoter to 
drive the expression of the shRNA’s, with the U6 promoter shown to be very active in 
undifferentiated hESCs (Xia, Zhang 2007). Following the first passage after transduction, 
antibiotic-resistant colonies were selected upon exposure to puromycin at a concentration of 
1µg/ml for 7 days. CDK2AP1 expression was then examined using qPCR (Figure 16.A), and 
Western blot (Figure 16.B). Based on qPCR analysis, we were able to achieve 96% knockdown 
of CDK2AP1, with statistical analysis indicating significant differences (p<0.05) in the 
expression patterns between hESCs transduced with the shRNA1 and the scshRNA (Figure 
16.A).  We also noted that the knockdown of CDK2AP1 resulted in a statistically significant 
reduction (p <0.05) in OCT4 and NANOG levels by 63.3% and 66.1% respectively (Figure 17). 
In addition, when a second CDK2AP1 specific shRNA was used we were able to achieve 98% 
knockdown which also resulted in a reduction (p < 0.05) in OCT4 and NANOG levels by 72.9% 
and 53% respectively.  This data suggests a role for CDK2AP1 in affecting pluripotent gene 
expression of hESCs. 
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A.  
 
B. 
 
Figure 16: CDK2AP1 is Successfully Downregulated in hESCs. A. H9 hESCs were 
transduced with a sc-shRNA or CDK2AP1-shRNA1. After 7 days of puromycin selection at 1 
µg/ml, total RNA was extracted and real time-qPCR was used to measure the expression of 
CDK2AP1. The cells that were transduced with CDK2AP1-shRNA1 had 96% reduction in 
CDK2AP1 expression (p-value <0.05).  Results are presented together with standard deviation 
from experiments conducted in triplicate.  B. Whole cell lysates were used to examine levels of 
CDK2AP1 protein in H9 hESCs transduced with CDK2AP1 specific shRNA1 (right lane) or a 
control (left). Cells that were transduced with CDK2AP1 specific shRNA1 had lower CDK2AP1 
protein levels.   
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A.  
 
 
B. 
 
 
 
 
  
 
 
Figure 17: Knockdown of CDK2AP1 in hESCs Reduces Levels of OCT4 and NANOG. A. H9 
hESCs that were transduced with CDK2AP1-shRNA1, CDK2AP1-shRNA2 or an empty vector (EV) 
were examined for CDK2AP1 knockdown and for OCT4 and NANOG expression. Knockdown of 
CDK2AP1 using CDK2AP1-shRNA1 and CDK2AP1-shRNA2 resulted in reduction in OCT4 and 
NANOG expression when compared with hESCs that were transduced with the empty vector (p-value  
< 0.05. Comparisons were made between EV and CDK2AP1-shRNA1 or EV and CDK2AP1-
shRNA2 transduced cells). Results are presented together with standard deviation from 
experiments conducted in triplicate. B. Whole cell lysates from H9s transduced with CDK2AP1-
shRNA1 (right lane) or empty vector (left) were examined by Western Analysis and demonstrated 
reduction in OCT4 and NANOG levels.   
GAPDH 
WT KD 
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Knockdown of CDK2AP1 Enhances EB Formation 
 Previous studies that were performed on mESCs showed that Cdk2ap1 knockout mESCs 
were resistant to differentiation and yielded lower number of embryoid bodies (EB) in which 
Oct4 was still active (Deshpande, Dai et al. 2009). These studies demonstrated the inability to 
silence Oct4 expression in 8-day old EBs derived from Cdk2ap1 knockout mESCs. We thus 
examined the effect of CDK2AP1 knockdown on EB formation and Oct4 gene expression in 
these EBs derived from hESCs. Using the hanging drop method, we generated EBs from H9 
hESCs transduced with either a scrambled shRNA or CDK2AP1-shRNA1. Our results indicate 
that a statistically significantly higher number of EBs (p <0.05) were generated from the 
knockdown when compared to wild-type cells, with parallel experiments conducted with human 
iPSCs yielding similar results (Figure 18). In addition, we observed a size difference between the 
EBs generated from wild type and knockdown hESCs, with the EBs generated from CDK2AP1 
knockdown hESCs larger in size (Figure 18). Interestingly, this outcome suggests a potentially 
different role for CDK2AP1 in human pluripotent stem cells as the downregulation of this 
protein in mESCs resulted in a reduction in the number of EBs obtained. In addition, the 
knockdown of CDK2AP1 in human pluripotent stem cells enhanced their differentiation 
capability, yielding a significantly higher number of EBs which could be used in subsequent 
steps that could yield multiple terminally differentiated cell types.  
Knockdown of CDK2AP1 in hESCs Results in Increased In Vitro Differentiation Potential.  
A hallmark of differentiation in EBs is the formation of the three germ layers (ectoderm, 
mesoderm, endoderm). We next examined the expression of germ layer-specific markers in the 
EBs generated from CDK2AP1 knockdown H9 hESCs by qPCR analysis. EBs generated from 
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CDK2AP1 knockdown hESCs had a statistically significantly higher expression (p<0.05) of 
markers of all the three germ layers, when compared with EBs obtained from wild type hESCs 
(Table 3). This was specifically apparent in the expression of the mesoderm marker T (increased 
27.6 fold) and in the ectoderm marker, SOX1 (increased by 67 fold). We also conducted 
histopathological analysis of the EBs generated from CDK2AP1 knockdown H9-hESCs. When 
compared with wild type EBs which consisted almost exclusively of neuroectoderm, EBs 
generated from CDK2AP1 knockdown H9-hESCs exhibited evidence of ectoderm and 
mesoderm differentiation (Figure 19). Taken together, these data demonstrated that the 
knockdown of CDK2AP1 enhanced the differentiation of hESCs and increased the expression of 
markers of all three germ layers in the derived EBs. To test whether CDK2AP1 is required for 
OCT4 silencing in the generated EBs, we collected 8-day old EBs generated from sc-shRNA H9 
hESCs and CDK2AP1-shRNA H9 hESCs and measured the levels of OCT4 expression using 
qPCR analysis. Our results indicate that OCT4 was equally silenced in both CDK2AP1 
knockdown and wild type EBs (Figure 20), thus indicating that CDK2AP1 is not required for 
OCT4 silencing during the differentiation of hESCs. 
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A. 
 
B. 
 
Figure 18: Knockdown of CDK2AP1 in hESCs Increases the Size and Number of 
Generated EBs. A. Representative EBs that were generated from wild-type and CDK2AP1-
knockdown H9- hESCs shown at the same magnification. Scale bar represents 100 µm. EBs 
generated from CDK2AP1 knockdown hESCs appeared larger in size. B. Knockdown of 
CDK2AP1 in hESC (left) and hiPSCs (right) increased the number of generated EBs (p < 0.05). 
Results are presented together with standard deviation from experiments conducted in triplicate. 
 
sc-shRNA EB CDK2AP1-shRNA EB
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Table 3: Knockdown of CDK2AP1 in H9-hESCs Results in EBs with Enhanced Expression 
of Genes Corresponding to the Three Germ Layers. Quantitative PCR data showing the effect 
of CDK2AP1 knockdown on the expression of the germ layers markers in EBs derived from H9 
hESCs. EBs obtained from sc-shRNA transduced H9s and EBs obtained from CDK2AP1-
shRNA were harvested and the expression of markers of germ layers (Endoderm: AFP and 
GATA4. Mesoderm: T and IGF2. Ectoderm: SOX1 and NESTIN) was examined by qPCR. 
Knockdown of CDK2AP1 significantly enhanced the expression of all markers of differentiation 
(p-value < 0.05). 
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Figure 19: Knockdown of CDK2AP1 Enhances Differentiation.  Shown are images of 
hematoxylin and eosin-stained histopathologic sections of EBs generated from CDK2AP1 
knockdown H9 hESCs. Representative differentiation is shown based (a) ectodermal 
(neuroepithelial) and (b) mesodermal (fibrous connective) germ layer formation.  Scale bar 
represents 100 µm. 
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Figure 20: CDK2AP1 is not Required for OCT4 Silencing During the Differentiation of 
hESCs. To investigate if CDK2AP1 is required for proper silencing of OCT4 during hESC, 8-
day old EBs generated from CDK2AP1 wild type (sc-shRNA) and knockdown (CDK2AP1-
shRNA) hESCs were harvested and the levels of CDK2AP1 and OCT4 measured by qPCR. 
Results indicate that CDK2AP1 knockdown hESCs were able to shut down OCT4 expression to 
the same levels seen in the wild type EBs (p-value = 0.88). Results are presented together with 
standard deviation from experiments conducted in triplicate. 
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Knockdown of CDK2AP1 in hESCs Reduces Proliferation and Alters Cell Cycle Profile 
Downregulation of Cdk2ap1 in mESCs resulted in an increase in proliferation with 
hypersphosphorylation of pRb (Kim, Deshpande et al. 2009). The differentiation capacity of 
these mESCs was extremely reduced and was only restored following the introduction of 
exogenous Cdk2ap1, or by expressing a mutated form of pRb that was resistant to 
phosphorylation (Kim, Deshpande et al. 2009). This study presented a clear manifestation of the 
strong relationship between cell cycle regulation, pluripotency and differentiation. Being an 
inhibitor of CDK2, we initially expected that knockdown of CDK2AP1 would increase 
proliferation of hESCs and also reduce their differentiation capacity by pushing them more 
towards self-renewal. However, as mentioned above, we found that the knockdown of 
CDK2AP1 enhanced differentiation potential of the hESCs. We thus decided to examine the 
effect of the knockdown on the proliferation and cell cycle profile of hESCs. 
Fifty thousand H9 hESCs that were transduced with either an empty vector or with a 
CDK2AP1 specific shRNA1 were seeded per well in a 12-well plate and were counted at 2 and 4 
days post seeding. We observed that the knockdown of CDK2AP1 significantly reduced the 
proliferation of hESCs (p<0.05) (Figure 21). Cell cycle analysis demonstrated that the 
knockdown of CDK2AP1 significantly decreased cells in the S phase from 23% in wild type 
cells to an average of 14.6% in CDK2AP1 shRNA1 transduced cells (p-value = 0.0007). In 
addition, knockdown resulted in a significant increase in the percentage of cells in the G2/M (p-
value = 0.0008) when compared with shRNA1 transduced cells from 36.7% to 45.6% (Figure 
22). 
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After we observed the significant increase in the percentage of CDK2AP1 knockdown 
hESCs that were in the G2/M phase of the cell cycle, we examined the protein levels of Cyclin 
A1 in those cells. It has been reported that increased Cyclin A1 can cause the accumulation of 
cells in the G2/M phase of the cell cycle, mitotic catastrophe and apoptosis (Rivera, A. et al. 
2006). Whole cell lysates of H9 hESCs that were transduced with an empty vector or CDK2AP1 
shRNA1 were examined for Cyclin A1 protein levels. We found that knockdown of CDK2AP1 
increased the levels of Cyclin A1 by two fold (Figure 23). We also examined the levels of 
phospho-Histone 3 (p-H3) which is detectable in cells that are in the late G2 and M phase of cell 
cycle (Van Hooser, Goodrich et al. 1998). Immunocytochemical analyses indicated that a 
significantly higher percentage (4.7%) of CDK2AP1knockdown H9-hESCs stained positive for 
p-H3, while only (2.6%) of wild-type hESCs were positive (p<0.05) (Figure 24). 
These results indicate that CDK2AP1 may play a different role in hESCs when compared 
to mESCs. In Cdk2ap1-/- mESCs, differentiation capacity was compromised, whereas we found 
that CDK2AP1 knockdown H9-hESCs had a significant reduction in the expression of the 
pluripotency genes, OCT4 and NANOG, and generated higher number of EBs which had higher 
expression of candidate markers of the three germ layers when they were differentiated. 
Cdk2ap1-/- mESCs seemed to favor self-renewal over differentiation, which was apparent in 
their faster cell cycle and the hyperphosphorylation of the pRb. On the other hand, our results 
indicate that CDK2AP1 knockdown H9-hESCs seem to favor differentiation over self-renewal, 
as evinced by their reduced proliferation and reduced pluripotency gene expression. 
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Figure 21: Knockdown of CDK2AP1 in hESCs Reduces Proliferation. Fifty thousand H9 
hESCs that were transduced with an empty vector (WT) or CDK2AP1 shRNA1 (KD) were 
seeded per well in a 12-well plate. Cells were harvested and counted in triplicates at 2 and 4 days 
post seeding. (*- p-value < 0.05. Comparisons were made between WT and KD cells at 
respective time points). Results are presented together with standard deviation from experiments 
conducted in triplicate. 
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Figure 22: Knockdown of CDK2AP1 in hESCs Increases Cells in the G2/M and Decreases 
Cells in the S Phase of the Cell Cycle. CDK2AP1 wild type and knockdown H9 hESCs were 
harvested and equal numbers were stained with propidium iodide (PI) and analyzed using an 
Accuri C6 flow cytometer. Results are presented together with standard deviation from 
experiments conducted in triplicate. (*= p < 0.05). 
  
 75 
 
 
Figure 23: Knockdown of CDK2AP1 in hESCs Increases Cyclin A levels.  Western blot (left) 
shows an increase in Cyclin A levels in the CDK2AP1 knockdown hESCs when compared to 
wild type cells. Densitometric analysis of the protein levels of the Western blot is presented in 
the right panel. 
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Figure 24: Knockdown of CDK2AP1 in H9 hESC Increases the Level of Phospho-Histone 
3. H9 hESCs were transduced with a scrambled shRNA (sc-shRNA) or with CDK2AP1-
shRNA1. Cells were fixed and stained using a phospho-Histone 3 specific antibody. Around 500 
cells were counted in randomly selected fields and the percentage of p-H3 positive cells was 
calculated. A.  Shows that the percentage of p-H3 positive cells. Results are presented together 
with standard deviation from experiments conducted in triplicate. B. Shows the p-H3 staining, 
DAPI, β-Tubulin and a merge picture in both sc-shRNA and CDK2AP1-shRNA transduced 
cells. Scale bar represents 50 µm.  
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Knockdown of CDK2AP1 in hESCs Results in an Increase in p53 Protein Levels and  
Reduces p21 mRNA Expression 
After we observed the increase in Cyclin A1 protein levels following CDK2AP1 
knockdown, we decided to examine the levels of p53 in CDK2AP1 knockdown hESCs. It has 
been reported that increased p53 levels may increase Cyclin A1 leading to the accumulation of 
cells in the G2/M phase (Rivera, A. et al. 2006). In addition, we suspected that following 
CDK2AP1 knockdown, its inhibition on CDK2 might be alleviated leading to upregulation of the 
oncogene E2F, which in turn could increase Cyclin A and p53 levels (Soucek, Pusch et al. 1997). 
Whole cell lysate from CDK2AP1 wild type and knockdown H9 hESCs were examined for p53 
protein levels by Western blot analysis. We found that knockdown of CDK2AP1 resulted in a 
1.76 fold increase in p53 protein levels (Figure 25).  
We next examined the expression of p21mRNA to test if it was affected by the increase 
in p53. Contrary to what was expected, qPCR analysis indicated that p21 mRNA levels were 
reduced by ~60% in the CDK2AP1 knockdown H9-hESC when compared with the wild type 
H9-hESCs (Figure 26). It has recently been reported that in hESCs, p53 can activate the micro-
RNA’s: miR-302a, miR-302b, miR-302c and miR-302d, which can subsequently downregulate 
the p21 mRNA when p53 is activated (Dolezalova, Mraz et al. 2012). This study clearly 
explained the reason behind the non-functional p53-p21 axis of the G1/S phase check point in 
hESCs compared to somatic cells, which activate p21 in response to p53 stabilization and arrest 
in the G1 phase of the cell cycle. Although we observed a decrease in p21 expression, we did not 
see an increase in G1 to S phase transition. It could be that CDK2AP1 knockdown have affected 
the levels of other G1 checkpoint regulators like p27 or p16. 
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Figure 25: Knockdown of CDK2AP1 in hESCs increases p53 levels.  Whole cell lysates of 
wild type and CDK2AP1 knockdown H9 hESCs were examined for p53 protein levels. We 
found that knockdown of CDK2AP1 increased p53 protein levels as shown by the western blot 
(left). Densitometric analysis of the protein level is presented in the right panel. 
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Figure 26: Knockdown of CDK2AP1 in hESCs Reduces p21 Expression. Quantitative PCR 
analysis showing the levels of CDK2AP1 and p21 expression in wild type and CDK2AP1 
knockdown H9 hESCs. Knockdown of CDK2AP1 resulted in a 63% reduction in p21 expression 
(p < 0.05. Comparisons were made between sc-shRNA and CDK2AP1-shRNA1 transduced cells 
for each gene analyzed).  Results are presented together with standard deviation from 
experiments conducted in triplicate. 
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Simultaneous Knockdown of CDK2AP1 and p53 Prevents the Reduction in OCT4 and 
NANOG Levels and Also Prevents the Accumulation in the G2/M Phase of the Cell Cycle. 
In a recent study, it was demonstrated that knockdown of p53 prevented retinoic acid 
mediated differentiation of hESCs (Jain, Allton et al. 2012). The expression of pluripotency 
markers, OCT4 and NANOG remained elevated even after 3 days of treatment with retinoic acid 
in the p53 knockdown hESCs. Further investigation revealed that upon the induction of 
differentiation in hESCs (by retinoic acid treatment), there was an enrichment in p53 binding to 
p53 responsive elements in the promoters of miR-34a and miR-145 (Jain, Allton et al. 2012). 
MiR-34a is known to exacerbate p53 activation by inhibiting the p53-inhibitor, SIRT-1 
(Yamakuchi, Ferlito et al. 2008), while miR-145 is known to suppress the expression of the 
pluripotency genes, OCT4, SOX2, and KLF4 in hESCs and promote differentiation (Xu, 
Papagiannakopoulos et al. 2009). Taken together, we expect that the reduced expression of the 
pluripotency genes, OCT4 and NANOG that is seen in the CDK2AP1 knockdown hESCs is due 
to p53 activation, which also affected the cell cycle profile and pluripotency. 
To investigate whether the observed phenotype seen in CDK2AP1 knockdown hESCs is 
p53 dependent, we co-transduced BG01v hESCs with p53 and CDK2AP1 shRNAs and assayed 
OCT4 and NANOG expression by qPCR analysis. The double knockdown cells did not silence 
OCT4 (p-value = 0.004) or NANOG (p-value= 0.0005) expression when compared with 
CDK2AP1 only knockdown cells (Figure 27). Similarly, introduction of exogenous CDK2AP1 
prevented the reduction in OCT4 and NANOG expression seen in CDK2AP1 knockdown hESCs 
(Figure 28). 
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In experiments conducted with H9-hESCs, we found that CDK2AP1 knockdown resulted 
in a decrease in the percentage of cells that were in the S phase and increased cells in the G2/M 
phase of the cell cycle (Figure 22). To test if this shift in the cell cycle is p53 dependent, we 
examined the cell cycle of H9 hESCs that were co-transduced with p53 and CDK2AP1 shRNAs. 
We found that these cells in which p53 and CDK2AP1 were downregulated did not accumulate 
in the G2/M phase and had a significantly higher percentage of cells in the S phase when 
compared to CDK2AP1 knockdown cells (Figure 29). We noted a slight delay in S-G2/M 
transition in the double knockdown cells, which could be due to abnormalities in DNA synthesis 
as both CDK2AP1 and p53 regulate DNA replication (Zhou and Privies, 2003) (Matsuo, 
Shintani et al., 2000). 
 
Discussion and Conclusions 
The function of CDK2AP1 as initially assessed in mESCs indicated an important role in 
the differentiation and self-renewal of pluripotent stem cells (Kim, Deshpande et al. 2009). Its 
deletion in mESCs resulted in an increase in self-renewal and a reduction in differentiation 
capacity, caused by a defect in the proper epigenetic silencing of Oct4 during differentiation due 
to the delocalization of the Nucleosome Remodeling and Deacetylation (NuRD) complex from 
Oct4 promoter (Deshpande, Dai et al. 2009). Therefore, it was concluded that Cdk2ap1 is 
required for epigenetic silencing of Oct4 during mESC differentiation. Another study 
demonstrated that, Cdk2ap1 
-/-
 mESCs failed to differentiate due to increased phosphorylation of 
pRb which lead to persistent self-renewal (Kim, Deshpande et al. 2009). Differentiation capacity 
was restored in those cells after introduction of an unphosphorylatable form of pRb or exogenous 
Cdk2ap1.  
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Figure 27: Downregulation of p53 Prevents the Reduction in OCT4 and NANOG 
Expression Seen in CDK2AP1 only Knockdown hESCs. BG01v hESCs were transduced with 
scrambled shRNA (sc-shRNA), CDK2AP1 shRNA or co-transduced with CDK2AP1 and p53 
shRNAs. The gene expression of CDK2AP1, OCT4, NANOG and p53 was analyzed in those 
cells by qPCR. We found that down regulating p53 with CDK2AP1 prevented the CDK2AP1-
knockdown induced reduction in OCT4 and NANOG levels (p < 0.05. Comparisons were made 
between EV and CDK2AP1-shRNA or CDK2AP1-shRNA and CDK2AP1-shRNA + shp53 
transduced cells for each gene analyzed). Results are presented together with standard deviation 
from experiments conducted in triplicate.  
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Figure 28: Introduction of Exogenous CDK2AP1Simultaneously with CDK2AP1 shRNA2 
Prevents Reduction in OCT4 and NANOG Expression. BG01v hESCs were transduced with 
sc-shRNA or with exogenous CDK2AP1 + CDK2AP1 shRNA2 and analyzed by qPCR for 
OCT4 and NANOG expression. Prevention of knockdown by introducing exogenous CDK2AP1 
prevents the reduction in OCT4 and NANOG expression seen in CDK2AP1 knockdown hESCs 
(p> 0.05. Comparisons were made between sc-shRNA and CDK2AP1-shRNA2 + CDK2AP1 for 
each gene analyzed). Results are presented together with standard deviation from experiments 
conducted in triplicate.  
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Figure 29: Simultaneous Knockdown of CDK2AP1 and p53 Prevents the G2/M 
Accumulation and the Decrease in S phase Seen in the CDK2AP1 only Knockdown hESCs. 
H9 hESCs were co-transduced with CDK2AP1 and p53 shRNAs, stained with propidium iodide 
and analyzed by flow cytometry to examine their cell cycle profile. Knockdown of CDK2AP1 in 
H9 hESCs resulted in a decrease in the percentage of cells in the S phase and increased cells in 
the G2/M phase of the cell cycle (Figure 22). When p53 is simultaneously downregulated with 
CDK2AP1, there was no reduction in cells in the S phase and no increase in cells in the G2/M 
phase of the cell cycle. Around 6% of the analyzed cells were in the sub G0/G1 phase of the cell 
cycle. Results are presented together with standard deviation from experiments conducted in 
triplicate. Cell cycle data of EV and CDK2AP1-shRNA transduced hESCs from figure 22 were 
included in this figure to facilitate comparison.   
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To investigate the function of CDK2AP1 in human pluripotent stem cell self-renewal, 
pluripotency and differentiation potential, we knocked down CDK2AP1 expression in multiple 
human pluripotent stem cells by RNA interference. Using a lentiviral approach, we were able to 
downregulate CDK2AP1 by 97%. When we examined the levels of OCT4 and NANOG in the 
CDK2AP1 knockdown hESCs, we found that the knockdown resulted in a decrease in the 
transcription of these genes (CDK2AP1-shRNA1 resulted in a 60% reduction in OCT4 and 
NANOG and when CDK2AP1-shRNA2 was used, knockdown resulted in a 70% reduction in 
OCT4 and 50% reduction in NANOG expression). These results indicated a possible difference in 
the role of CDK2AP1 in hESCs when compared to mESC, in which when Cdk2ap1 was deleted, 
Oct4 expression was sustained (Deshpande, Dai et al. 2009).  
Our results also indicated that CDK2AP1 knockdown hESCs had a greater propensity to 
differentiate when EB formation was induced. When we examined the expression of markers of 
the germ layers in 18-21 day old EBs, we found that EBs generated from CDK2AP1 knockdown 
hESCs exhibited higher expression of candidate markers of all the three germ layers. The 
difference was especially evident in the expression of mesoderm (27.6 fold increase in T) and in 
the ectoderm markers (67.2 fold increase in SOX1). Histopathological analysis also revealed that 
EBs generated from CDK2AP1 knockdown hESCs primarily demonstrated mesoderm and 
ectoderm differentiation, while EBs generated from wild type hESCs routinely demonstrated 
exclusive differentiation towards neuroectoderm. Taken together, our results indicate that 
knockdown of CDK2AP1 in hESCs enhances differentiation by yielding more EBs that have 
significantly higher expression of markers of all three germ layers. 
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Given the close connection between cell cycle and pluripotency, we next aimed to examine 
the effect of CDK2AP1 knockdown on the proliferation and the cell cycle of hESCs. We initially 
observed that CDK2AP1knockdown hESCs were proliferating significantly slower and had to be 
sub-cultured less frequently. When the cell cycle profile of these cells was examined by 
propidium iodide staining and flow cytometry analysis, we found that these cells accumulated in 
the G2/M phase of the cell cycle and had a significantly lower percentage of cells in the S phase 
of the cell cycle. We also found that a higher percentage of these cells stained positive for p-H3, 
which is detected in cells that are in the late G2 and M phase of the cell cycle. In addition, Cyclin 
A1 and p53 protein levels were increased following CDK2AP1 knockdown by 2 and 1.76 folds 
respectively. It has been reported previously, that increased p53 levels can increase Cyclin 
A1which in turn can cause G2/M arrest (Rivera, A. et al. 2006).  
Increased p53 levels can also cause arrest in the G2/M phase of the cell cycle in a number 
of ways that are independent of Cyclin A1. It is known that when levels of p53 are increased, it 
results in the induction of the expression of the 14-3-3σ, a gene originally discovered through its 
expression in differentiating epithelial cells and a member of the 14-3-3 protein family (Prasad, 
Valverius et al. 1992, Hermeking, Lengauer et al. 1997). Through a p53-responsive element 
located 1.8 kb upstream of its transcription start site, 14-3-3σ is induced upon p53 binding and 
inhibits G2/M progression by sequestering CDK1 in the cytoplasm (Hermeking, Lengauer et al. 
1997). In addition, p53 can exert its inhibition of the G2/M transition by decreasing intracellular 
levels of cyclin B1 protein and attenuating the activity of the cyclin B1 promoter (Innocente, 
Abrahamson et al. 1999). Furthermore, p53 has also been shown to repress the promoter of 
CDK1, which is another way through which G2/M transition is regulated by p53 (Passalaris, 
Benanti et al. 1999). 
 87 
 
We observed that when p53 and CDK2AP1 were both downregulated, there was minimal 
reduction in OCT4 and NANOG expression, suggesting the observed reduction in their levels 
following CDK2AP1 may be p53 dependent. A recent study showed that upon the induction of 
differentiation of hESCs, there was an enrichment in p53 binding to p53 responsive elements in 
the promoters of miR-145 (Jain, Allton et al. 2012), which then suppresses the expression of the 
pluripotency genes, OCT4, SOX2 and KLF4 in hESCs and promotes differentiation (Xu, 
Papagiannakopoulos et al. 2009). In addition, when the cell cycle profile of H9 hESCs that were 
co-transduced with CDK2AP1 and p53 shRNAs was examined, we found that the introduction of 
the p53 shRNA prevented the decrease in S phase and the increase in the G2/M phase of the cell 
cycle that was seen in the CDK2AP1 knockdown only hESCs. This data suggests that the change 
in the cell cycle profile following CDK2AP1 knockdown may be caused due to an increase in 
p53 levels. Being an inhibitor of CDK2 we expect that the knockdown of CDK2AP1 might have 
temporarily alleviated this inhibition leading to faster progression into S phase and an aberrant 
upregulation of the oncogene E2F. This in turn may cause a p16 (ARF) mediated degradation of 
the p53 inhibitor MDM2 leading to an increase in p53 levels (figure: 30) (Zhang, Xiong et al. 
1998).  
Although CDK2AP1knockdown in hESCs resulted in a decrease in OCT4 and NANOG 
levels, these cells differentiated better than wild types. The knockdown of CDK2AP1 improved 
the generation of EBs and enhanced the expression of all tested markers of the three germ layers. 
Overall, our results indicate that hESCs exhibit reduced self-renewal potential following 
CDK2AP1 knockdown, a significantly lower percentage of cells in the S phase, and higher 
percentage were in the G2/M phase when compared to wild type cells. Therefore,  our results 
lead us to the conclusion that the knockdown of CDK2AP1 in hESCs lowers the threshold of 
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differentiation by decreasing self-renewal and increasing the susceptibility of these cells to 
differentiate. 
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Figure 30: The Expected Model Following CDK2AP1 Knockdown in hESCs. CDK2AP1 knockdown 
may result in an increase in CDK2 activity leading to upregulation of the oncogene E2F. This will in turn 
increase p53 levels. Increased p53 levels in hESCs has been reported to result in G2/M arrest and to 
increase the expression of the miRNAs 302, 34a and 145. MiR-302 is known to downregulate p21, thus 
preventing the G1 arrest in hESCs. MiRNA’s 34a and 145 downregulate the pluripotency genes, LIN28, 
OCT4, NANOG and SOX2. 
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CHAPTER 4 
 
 
 
Conclusions and Future Directions 
 
Conclusions: 
 CDK2AP1 has been shown to mainly function as a cell cycle regulator that inhibits 
CDK2 by targeting it for proteolysis, therefore inhibiting the progression from G1 to S phase. It 
has also been reported that CDK2AP1 binds the DNA polymerase/alpha primase complex and 
inhibits the initiation step of DNA synthesis. CDK2AP1 overexpression in a number of cancer 
cell lines decreased invasion and reduced proliferation. In the first  study we aimed to investigate 
the effect of CDK2AP1 downregulation on the growth of normal primary human fibroblasts. The 
results obtained from the experiments support the following conclusions: 
 Knockdown of CDK2AP1 in primary HDFs reduces proliferation 
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 CDK2AP1 knockdown causes an accumulation of cells in the G1 phase of the cell 
cycle 
 Knockdown of CDK2AP1 in primary HDFs induced premature senescence 
 When compared to wild type HDFs, CDK2AP1 knockdown HDFs have higher ɣ-
H2AX signal, representative of DNA damage 
 Knockdown of CDK2AP1increases mRNA and protein levels of p53 
 Knockdown of CDK2AP1 increases mRNA levels of BAX, PUMA and p21 
 The observed senescence and increase in G1 phase of the cell cycle following 
CDK2AP1 knockdown is p53 dependent 
 
In the second study, we investigated the effect of CDK2AP1 knockdown on the self-
renewal and pluripotency of hESCs. Recent reports showed that CDK2AP1 plays an important 
role during the differentiation of mESCs. Cdk2ap1 null mESCs fail to differentiate properly, and 
experienced persistent self-renewal, evident by increased proliferation and hyper-
phosphorylation of the retinoblastoma protein. It was also shown that CDK2AP1 is required for 
silencing of Oct4 expression during mESC differentiation. Based on these findings, it seems that 
deletion of Cdk2ap1 in mESCs favors self-renewal over differentiation. To investigate the effect 
of CDK2AP1 downregulation on the self-renewal and pluripotency of hESC, we used lentiviral 
delivery of CDK2AP1 specific shRNA to create stable CDK2AP1 knockdown hESCs cell lines. 
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Series of experiments conducted with the CDK2AP1 knockdown hESCs led to results which 
supports the following conclusions: 
 CDK2AP1 knockdown lowers the differentiation threshold of  hESCs. This was 
demonstrated by the reduced levels of OCT4 and NANOG and by the enhanced ability 
of these cells to differentiate and form EBs. 
 CDK2AP1 knockdown increases the expression of all tested markers of the three germ 
layers in the generated EBs (Endoderm: AFP and GATA4. Mesoderm: T and IGF2. 
Ectoderm: SOX1 and NESTIN).  
 The knockdown of CDK2AP1 significantly slowed cell division in hESCs and reduced 
the percentage of cells in the S phase and significantly increased the percentage of cells 
in the G2/M phase of the cell cycle. 
 CDK2AP1 knockdown led to increase in Cyclin A levels. 
 CDK2AP1 knockdown increased p53 protein levels 
 Simultaneous knockdown of CDK2AP1 and p53 prevents the reduction in OCT4 and 
NANOG levels 
 Simultaneous knockdown of CDK2AP1 and p53 prevents the reduction of cells in the S 
phase and the increase in the G2/M phase of the cell cycle. 
 
Future Directions 
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Human pluripotent stem cells that include hESCs and hiPSCs represent a good alternative 
to adult stem cells as a source of an unlimited supply of well-defined pluripotent stem cells that 
can generate clinical-grade, transplantable, lineage-specific cells. Our data demonstrated 
enhanced differentiation potential when CDK2AP1 is downregulated in hESCs. Higher numbers 
of EBs were obtained in which levels of markers of all three germ layers were significantly 
higher. Neuroectoderm markers, Sox1 and Nestin, expression was increased 67 and 4 folds 
respectively in CDK2AP1 knockdown EBs when compared to wild type EBs. We therefore 
propose the investigation of the effect of CDK2AP1 knockdown on the differentiation of hPSCs 
to neural progenitor cells. We expect that due to increased expression of these markers in the 
knockdown EBs, generation of neural progenitors would be enhanced. This study could be 
accomplished through the following specific aims: 
 Specific Aim 1: Differentiate both CDK2AP1 WT and knockdown hPSCs to neural 
progenitors. 
Using established differentiation protocols both wild type and knockdown cells would be 
directed to differentiate to form neural progenitors. The purpose of this aim is to assess the 
ability of CDK2AP1 knockdown hPSCs to differentiate efficiently to neural progenitors. The 
quantity and the quality of the generated neural progenitors will be investigated. The generated 
cells will be examined for the formation of neural rosettes, a characteristic of neural progenitors. 
The purity of the generated neural progenitors will be examined by flow cytometry by measuring 
the levels of candidate neural progenitor markers (NESTIN and MUSASHI1). In addition, qPCR 
analysis will be conducted to compare the marker expression between wild type and knockdown 
hPSCs. 
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 Specific Aim 2: Examine the ability of generated neural progenitors to efficiently form 
multiple cell types of the nervous system. 
In experiments conducted under this aim, CDK2AP1 knockdown and WT neural progenitors will 
be differentiated in culture to form neurons, oligodendrocytes and astrocytes. Gene expression 
analysis, immunocytochemistry, and FACS analysis will be utilized to compare expression of 
multiple markers specific to the different differentiated cell types. In addition, the potential of 
wildtype and the CDK2AP1 knockdown neural progenitors to form specialized neuronal cells 
like motor neurons and dopaminergic neurons for clinical applications will be compared. 
 
Previous studies have focused on investigating the potential of overexpressing CDK2AP1 
in cancer cell lines and determine its effect of cell growth and apoptosis. However, few studies 
have investigated the effect of CDK2AP1 knockdown on cancer cell lines In studies conducted 
with primary human dermal fibroblast, we found that the knockdown of CDK2AP1 induced 
premature senescence, reduced proliferation and increased the expression of p53, p21 and the 
p53-responsive apoptotic genes, BAX and PUMA. We thus propose to investigate the effect of 
CDK2AP1 downregulation on the proliferation characteristics of a primary cancer cell line. This 
study will be accomplished through the following specific aims: 
 Specific Aim 1: Examine the effect of CDK2AP1 knockdown on a human primary 
cancer cell line. 
A primary cancer cell line (e.g. breast cancer cell line) will be transduced with a scrambled 
sequence shRNA or an shRNA directed against CDK2AP1. After confirming successful 
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knockdown, the effect of the knockdown on cell proliferation will be examined by measuring 
doubling time, MTT assay or BrdU incorporation assay. In addition, the cell cycle profile of 
knockdown and wild type cells will be compared. Next, the effect of CDK2AP1 knockdown on 
the levels of cell cycle regulators like, p53, p21, p16, BAX and PUMA will be examined by gene 
expression and Western analysis. Cell invasion assay will also be performed to determine the 
effect of the knockdown on the invasiveness of the cancer cells. 
 Specific Aim 2: Utilize an in vivo model to examine the effect of CDK2AP1 knockdown 
on tumor formation. 
CDK2AP1 wild type and knockdown cells will be subcutaneously injected into nude mice and 
tumor growth monitored. We have observed decreased BrdU incorporation when CDK2AP1 was 
downregulated in primary fibroblasts and increased expression of the apoptotic genes BAX and 
PUMA. We will thus conduct experiments to monitor proliferation and apoptosis in the 
CDK2AP1 knockdown tumor cells by performing BrdU and TUNEL assay on tumor tissue.  
  
 96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bibliography  
 97 
 
 
 
 
 
 
Literature Cited 
 
 
 
 
Becker, K. A., et al. "Self-Renewal of Human Embryonic Stem Cells is Supported by a 
Shortened G1 Cell Cycle Phase." Journal of cellular physiology 209.3 (2006): 883-93. 
 
Becker, K. A., et al. "Establishment of Histone Gene Regulation and Cell Cycle Checkpoint 
Control in Human Embryonic Stem Cells." Journal of cellular physiology 210.2 (2007): 517-26. 
 
Boland, M. J., et al. "Adult Mice Generated from Induced Pluripotent Stem Cells." Nature 
461.7260 (2009): 91-4. 
 
Boyer, L. A., et al. "Core Transcriptional Regulatory Circuitry in Human Embryonic Stem 
Cells." Cell 122.6 (2005): 947-56. 
 
Byrne, J. A., et al. "Producing Primate Embryonic Stem Cells by Somatic Cell Nuclear 
Transfer." Nature 450.7169 (2007): 497-502. 
 
Calder, A., et al. "Lengthened G1 Phase Indicates Differentiation Status in Human Embryonic 
Stem Cells." Stem cells and development 22.2 (2013): 279-95. 
 
Calegari, F., et al. "Selective Lengthening of the Cell Cycle in the Neurogenic Subpopulation of 
Neural Progenitor Cells during Mouse Brain Development." The Journal of neuroscience : the 
official journal of the Society for Neuroscience 25.28 (2005): 6533-8. 
 
Calegari, F., and W. B. Huttner. "An Inhibition of Cyclin-Dependent Kinases that Lengthens, but 
does Not Arrest, Neuroepithelial Cell Cycle Induces Premature Neurogenesis." Journal of cell 
science 116.Pt 24 (2003): 4947-55. 
 
Chavez, L., et al. "In Silico Identification of a Core Regulatory Network of OCT4 in Human 
Embryonic Stem Cells using an Integrated Approach." BMC genomics 10 (2009): 314. 
 
Chin, M. H., et al. "Induced Pluripotent Stem Cells and Embryonic Stem Cells are Distinguished 
by Gene Expression Signatures." Cell stem cell 5.1 (2009): 111-23. 
 
Choi, M. G., et al. "Decreased Expression of p12 is Associated with More Advanced Tumor 
Invasion in Human Gastric Cancer Tissues." European surgical research.Europaische 
chirurgische Forschung.Recherches chirurgicales europeennes 42.4 (2009): 223-9. 
 98 
 
 
Crook, J. M., et al. "The Generation of Six Clinical-Grade Human Embryonic Stem Cell Lines." 
Cell stem cell 1.5 (2007): 490-4. 
 
Dimos, J. T., et al. "Induced Pluripotent Stem Cells Generated from Patients with ALS can be 
Differentiated into Motor Neurons." Science (New York, N.Y.) 321.5893 (2008): 1218-21. 
 
Dimri, G. P., et al. "A Biomarker that Identifies Senescent Human Cells in Culture and in Aging 
Skin in Vivo." Proceedings of the National Academy of Sciences of the United States of 
America 92.20 (1995): 9363-7. 
 
Dolezalova, D., et al. "MicroRNAs Regulate p21(Waf1/Cip1) Protein Expression and the DNA 
Damage Response in Human Embryonic Stem Cells." Stem cells (Dayton, Ohio) 30.7 (2012): 
1362-72. 
 
Ebert, A. D., et al. "Induced Pluripotent Stem Cells from a Spinal Muscular Atrophy Patient." 
Nature 457.7227 (2009): 277-80. 
 
Edel, M. J., et al. "Rem2 GTPase Maintains Survival of Human Embryonic Stem Cells as Well 
as Enhancing Reprogramming by Regulating p53 and Cyclin D1." Genes & development 24.6 
(2010): 561-73. 
 
Faast, R., et al. "Cdk6-Cyclin D3 Activity in Murine ES Cells is Resistant to Inhibition by 
p16(INK4a)." Oncogene 23.2 (2004): 491-502. 
 
Farra, N., et al. "Rett Syndrome Induced Pluripotent Stem Cell-Derived Neurons Reveal Novel 
Neurophysiological Alterations." Molecular psychiatry 17.12 (2012): 1261-71. 
 
Filipczyk, A. A., et al. "Differentiation is Coupled to Changes in the Cell Cycle Regulatory 
Apparatus of Human Embryonic Stem Cells." Stem cell research 1.1 (2007): 45-60. 
 
Fluckiger, A. C., et al. "Cell Cycle Features of Primate Embryonic Stem Cells." Stem cells 
(Dayton, Ohio) 24.3 (2006): 547-56. 
 
Fujii-Yamamoto, H., et al. "Cell Cycle and Developmental Regulations of Replication Factors in 
Mouse Embryonic Stem Cells." The Journal of biological chemistry 280.13 (2005): 12976-87. 
 
Gurdon, J. B., R. A. Laskey, and O. R. Reeves. "The Developmental Capacity of Nuclei 
Transplanted from Keratinized Skin Cells of Adult Frogs." Journal of embryology and 
experimental morphology 34.1 (1975): 93-112. 
 
Haigis, K. M., & Sweet-Cordero, A. (2011). New insights into oncogenic stress. Nature 
Genetics, 43(3), 177-178. 
 
 99 
 
Hanna, J., et al. "Direct Cell Reprogramming is a Stochastic Process Amenable to Acceleration." 
Nature 462.7273 (2009): 595-601. 
 
Hermeking, H., et al. "14-3-3 Sigma is a p53-Regulated Inhibitor of G2/M Progression." 
Molecular cell 1.1 (1997): 3-11. 
 
Hinchcliffe, E. H., and G. Sluder. "Two for Two: Cdk2 and its Role in Centrosome Doubling." 
Oncogene 21.40 (2002): 6154-60. 
 
Hong, H., et al. "Suppression of Induced Pluripotent Stem Cell Generation by the p53-p21 
Pathway." Nature 460.7259 (2009): 1132-5. 
 
Hu, M. G., et al. "Role of p12(CDK2-AP1) in Transforming Growth Factor-beta1-Mediated 
Growth Suppression." Cancer research 64.2 (2004): 490-9. 
 
Ichida, J. K., et al. "A Small-Molecule Inhibitor of Tgf-Beta Signaling Replaces sox2 in 
Reprogramming by Inducing Nanog." Cell stem cell 5.5 (2009): 491-503. 
 
Innocente, S. A., et al. "P53 Regulates a G2 Checkpoint through Cyclin B1." Proceedings of the 
National Academy of Sciences of the United States of America 96.5 (1999): 2147-52. 
 
Inomata, K., et al. "Genotoxic Stress Abrogates Renewal of Melanocyte Stem Cells by 
Triggering their Differentiation." Cell 137.6 (2009): 1088-99. 
 
Iyer, S., et al. "Stem Cell-Based Models and Therapies for Neurodegenerative Diseases." Critical 
Reviews in Biomedical Engineering 37.4-5 (2009): 321-53. 
 
Jain, A. K., et al. "P53 Regulates Cell Cycle and microRNAs to Promote Differentiation of 
Human Embryonic Stem Cells." PLoS biology 10.2 (2012): e1001268. 
 
Kaji, K., et al. "The NuRD Component Mbd3 is Required for Pluripotency of Embryonic Stem 
Cells." Nature cell biology 8.3 (2006): 285-92. 
 
Kang, L., et al. "IPS Cells can Support Full-Term Development of Tetraploid Blastocyst-
Complemented Embryos." Cell stem cell 5.2 (2009): 135-8. 
 
Kim, Y., et al. "P12(CDK2-AP1) Mediates DNA Damage Responses Induced by Cisplatin." 
Oncogene 24.3 (2005): 407-18. 
 
Kim, Y., et al. "Mutation of Cys105 Inhibits Dimerization of p12CDK2-AP1 and its Growth 
Suppressor Effect." The Journal of biological chemistry 280.24 (2005): 23273-9. 
 
Kirby, D. M., et al. "Leigh Disease Caused by the Mitochondrial DNA G14459A Mutation in 
Unrelated Families." Annals of Neurology 48.1 (2000): 102-4. 
 
 100 
 
Koledova, Z., et al. "Cell-Cycle Regulation in Embryonic Stem Cells: Centrosomal Decisions on 
Self-Renewal." Stem cells and development 19.11 (2010): 1663-78. 
 
Laflamme, M. A., et al. "Cardiomyocytes Derived from Human Embryonic Stem Cells in Pro-
Survival Factors Enhance Function of Infarcted Rat Hearts." Nature biotechnology 25.9 (2007): 
1015-24. 
 
Lange, C., W. B. Huttner, and F. Calegari. "Cdk4/cyclinD1 Overexpression in Neural Stem Cells 
Shortens G1, Delays Neurogenesis, and Promotes the Generation and Expansion of Basal 
Progenitors." Cell stem cell 5.3 (2009): 320-31. 
 
Lavin, M. F., and N. Gueven. "The Complexity of p53 Stabilization and Activation." Cell death 
and differentiation 13.6 (2006): 941-50. 
 
Le Guezennec, X., et al. "MBD2/NuRD and MBD3/NuRD, Two Distinct Complexes with 
Different Biochemical and Functional Properties." Molecular and cellular biology 26.3 (2006): 
843-51. 
 
Li, J. Y., et al. "Critical Issues of Clinical Human Embryonic Stem Cell Therapy for Brain 
Repair." Trends in neurosciences 31.3 (2008): 146-53. 
 
Lin, T., et al. "P53 Induces Differentiation of Mouse Embryonic Stem Cells by Suppressing 
Nanog Expression." Nature cell biology 7.2 (2005): 165-71. 
 
Lowry, W. E., and W. L. Quan. "Roadblocks En Route to the Clinical Application of Induced 
Pluripotent Stem Cells." Journal of cell science 123.Pt 5 (2010): 643-51. 
 
Maimets, T., et al. "Activation of p53 by Nutlin Leads to Rapid Differentiation of Human 
Embryonic Stem Cells." Oncogene 27.40 (2008): 5277-87. 
 
Mali, P., et al. "Improved Efficiency and Pace of Generating Induced Pluripotent Stem Cells 
from Human Adult and Fetal Fibroblasts." Stem cells (Dayton, Ohio) 26.8 (2008): 1998-2005. 
 
Marchetto, M. C., et al. "Transcriptional Signature and Memory Retention of Human-Induced 
Pluripotent Stem Cells." PloS one 4.9 (2009): e7076. 
 
Matsuo, K., et al. "P12(DOC-1), a Growth Suppressor, Associates with DNA Polymerase 
alpha/primase." FASEB journal : official publication of the Federation of American Societies for 
Experimental Biology 14.10 (2000): 1318-24. 
 
Meng, W., et al. "Downregulation of TGF-Beta Receptor Types II and III in Oral Squamous Cell 
Carcinoma and Oral Carcinoma-Associated Fibroblasts." BMC cancer 11 (2011): 88. 
 
Miura, K., et al. "Variation in the Safety of Induced Pluripotent Stem Cell Lines." Nature 
biotechnology 27.8 (2009): 743-5. 
 101 
 
 
Miura, T., et al. "Monitoring Early Differentiation Events in Human Embryonic Stem Cells by 
Massively Parallel Signature Sequencing and Expressed Sequence Tag Scan." Stem cells and 
development 13.6 (2004): 694-715. 
 
Muller, C., and A. Leutz. "Chromatin Remodeling in Development and Differentiation." Current 
opinion in genetics & development 11.2 (2001): 167-74. 
 
Murray-Zmijewski, F., E. A. Slee, and X. Lu. "A Complex Barcode Underlies the Heterogeneous 
Response of p53 to Stress." Nature reviews.Molecular cell biology 9.9 (2008): 702-12. 
 
Nakajima, F., K. Tokunaga, and N. Nakatsuji. "Human Leukocyte Antigen Matching 
Estimations in a Hypothetical Bank of Human Embryonic Stem Cell Lines in the Japanese 
Population for use in Cell Transplantation Therapy." Stem cells (Dayton, Ohio) 25.4 (2007): 
983-5. 
 
Neganova, I., et al. "Expression and Functional Analysis of G1 to S Regulatory Components 
Reveals an Important Role for CDK2 in Cell Cycle Regulation in Human Embryonic Stem 
Cells." Oncogene 28.1 (2009): 20-30. 
 
Passalaris, T. M., et al. "The G(2) Checkpoint is Maintained by Redundant Pathways." 
Molecular and cellular biology 19.9 (1999): 5872-81. 
 
Peng, H., et al. "Loss of p12CDK2-AP1 Expression in Human Oral Squamous Cell Carcinoma 
with Disrupted Transforming Growth Factor-Beta-Smad Signaling Pathway." Neoplasia (New 
York, N.Y.) 8.12 (2006): 1028-36. 
 
Perrier, A. L., et al. "Derivation of Midbrain Dopamine Neurons from Human Embryonic Stem 
Cells." Proceedings of the National Academy of Sciences of the United States of America 101.34 
(2004): 12543-8. 
 
Prasad, G. L., et al. "Complementary DNA Cloning of a Novel Epithelial Cell Marker Protein, 
HME1, that may be Down-Regulated in Neoplastic Mammary Cells." Cell growth & 
differentiation : the molecular biology journal of the American Association for Cancer Research 
3.8 (1992): 507-13. 
 
Price, B. D., L. Hughes-Davies, and S. J. Park. "Cdk2 Kinase Phosphorylates Serine 315 of 
Human p53 in Vitro." Oncogene 11.1 (1995): 73-80. 
 
Qi, J., et al. "MicroRNAs Regulate Human Embryonic Stem Cell Division." Cell cycle 
(Georgetown, Tex.) 8.22 (2009): 3729-41. 
 
Ramalho-Santos, M., et al. ""Stemness": Transcriptional Profiling of Embryonic and Adult Stem 
Cells." Science (New York, N.Y.) 298.5593 (2002): 597-600. 
 
 102 
 
Resnitzky, D., and S. I. Reed. "Different Roles for Cyclins D1 and E in Regulation of the G1-to-
S Transition." Molecular and cellular biology 15.7 (1995): 3463-9. 
 
Reubinoff, B. E., et al. "Embryonic Stem Cell Lines from Human Blastocysts: Somatic 
Differentiation in Vitro." Nature biotechnology 18.4 (2000): 399-404. 
 
Rivera, A., et al. "Cyclin A1 is a p53-Induced Gene that Mediates Apoptosis, G2/M Arrest, and 
Mitotic Catastrophe in Renal, Ovarian, and Lung Carcinoma Cells." Cellular and molecular life 
sciences : CMLS 63.12 (2006): 1425-39. 
 
Rowland, B. D., R. Bernards, and D. S. Peeper. "The KLF4 Tumour Suppressor is a 
Transcriptional Repressor of p53 that Acts as a Context-Dependent Oncogene." Nature cell 
biology 7.11 (2005): 1074-82. 
 
Ruiz, S., et al. "A High Proliferation Rate is Required for Cell Reprogramming and Maintenance 
of Human Embryonic Stem Cell Identity." Current biology : CB 21.1 (2011): 45-52. 
 
Sakaguchi, K., et al. "DNA Damage Activates p53 through a Phosphorylation-Acetylation 
Cascade." Genes & development 12.18 (1998): 2831-41. 
 
Savatier, P., et al. "Contrasting Patterns of Retinoblastoma Protein Expression in Mouse 
Embryonic Stem Cells and Embryonic Fibroblasts." Oncogene 9.3 (1994): 809-18. 
 
Savatier, P., et al. "Withdrawal of Differentiation Inhibitory activity/leukemia Inhibitory Factor 
Up-Regulates D-Type Cyclins and Cyclin-Dependent Kinase Inhibitors in Mouse Embryonic 
Stem Cells." Oncogene 12.2 (1996): 309-22. 
 
Schneider, C. A., W. S. Rasband, and K. W. Eliceiri. "NIH Image to ImageJ: 25 Years of Image 
Analysis." Nature methods 9.7 (2012): 671-5. 
 
Schratt, G., et al. "Serum Response Factor is Required for Immediate-Early Gene Activation Yet 
is Dispensable for Proliferation of Embryonic Stem Cells." Molecular and cellular biology 21.8 
(2001): 2933-43. 
 
Sengupta, S., et al. "MicroRNA 92b Controls the G1/S Checkpoint Gene p57 in Human 
Embryonic Stem Cells." Stem cells (Dayton, Ohio) 27.7 (2009): 1524-8. 
 
Sharov, A. A., et al. "Transcriptome Analysis of Mouse Stem Cells and Early Embryos." PLoS 
biology 1.3 (2003): E74. 
 
Sherr, C. J. "The INK4a/ARF Network in Tumour Suppression." Nature reviews.Molecular cell 
biology 2.10 (2001): 731-7. 
 
 103 
 
Shintani, S., et al. "Reduction of p12DOC-1 Expression is a Negative Prognostic Indicator in 
Patients with Surgically Resected Oral Squamous Cell Carcinoma." Clinical cancer research : an 
official journal of the American Association for Cancer Research 7.9 (2001): 2776-82. 
 
Shintani, S., et al. "P12(DOC-1) is a Novel Cyclin-Dependent Kinase 2-Associated Protein." 
Molecular and cellular biology 20.17 (2000): 6300-7. 
 
Smith, A. G. "Embryo-Derived Stem Cells: Of Mice and Men." Annual Review of Cell and 
Developmental Biology 17 (2001): 435-62. 
 
Soucek, T., et al. "Deregulated Expression of E2F-1 Induces Cyclin A- and E-Associated Kinase 
Activities Independently from Cell Cycle Position." Oncogene 14.19 (1997): 2251-7. 
 
Spitalieri, P., et al. "Rescue of Murine Silica-Induced Lung Injury and Fibrosis by Human 
Embryonic Stem Cells." The European respiratory journal : official journal of the European 
Society for Clinical Respiratory Physiology 39.2 (2012): 446-57. 
 
Spruijt, C. G., et al. "CDK2AP1/DOC-1 is a Bona Fide Subunit of the Mi-2/NuRD Complex." 
Molecular bioSystems 6.9 (2010): 1700-6. 
 
Stead, E., et al. "Pluripotent Cell Division Cycles are Driven by Ectopic Cdk2, Cyclin A/E and 
E2F Activities." Oncogene 21.54 (2002): 8320-33. 
 
Takagi, Y., et al. "Dopaminergic Neurons Generated from Monkey Embryonic Stem Cells 
Function in a Parkinson Primate Model." The Journal of clinical investigation 115.1 (2005): 102-
9. 
 
Takahashi, K., et al. "Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by 
Defined Factors." Cell 131.5 (2007): 861-72. 
 
Takahashi, K., and S. Yamanaka. "Induction of Pluripotent Stem Cells from Mouse Embryonic 
and Adult Fibroblast Cultures by Defined Factors." Cell 126.4 (2006): 663-76. 
 
Taylor, C. J., et al. "Banking on Human Embryonic Stem Cells: Estimating the Number of Donor 
Cell Lines Needed for HLA Matching." Lancet 366.9502 (2005): 2019-25. 
 
Thomson, J. A., et al. "Embryonic Stem Cell Lines Derived from Human Blastocysts." Science 
(New York, N.Y.) 282.5391 (1998): 1145-7. 
 
Tong, J. K., et al. "Chromatin Deacetylation by an ATP-Dependent Nucleosome Remodelling 
Complex." Nature 395.6705 (1998): 917-21. 
 
Tsuji, T., et al. "Cloning, Mapping, Expression, Function, and Mutation Analyses of the Human 
Ortholog of the Hamster Putative Tumor Suppressor Gene Doc-1." The Journal of biological 
chemistry 273.12 (1998): 6704-9. 
 104 
 
 
Tsuji-Takayama, K., et al. "Demethylating Agent, 5-Azacytidine, Reverses Differentiation of 
Embryonic Stem Cells." Biochemical and biophysical research communications 323.1 (2004): 
86-90. 
 
Turinetto, V., et al. "High Basal gammaH2AX Levels Sustain Self-Renewal of Mouse 
Embryonic and Induced Pluripotent Stem Cells." Stem cells (Dayton, Ohio) 30.7 (2012): 1414-
23. 
 
Utikal, J., et al. "Immortalization Eliminates a Roadblock during Cellular Reprogramming into 
iPS Cells." Nature 460.7259 (2009): 1145-8. 
 
Van Hooser, A., et al. "Histone H3 Phosphorylation is Required for the Initiation, but Not 
Maintenance, of Mammalian Chromosome Condensation." Journal of cell science 111 ( Pt 23).Pt 
23 (1998): 3497-506. 
 
White, J., and S. Dalton. "Cell Cycle Control of Embryonic Stem Cells." Stem cell reviews 1.2 
(2005): 131-8. 
 
White, J., et al. "Developmental Activation of the Rb-E2F Pathway and Establishment of Cell 
Cycle-Regulated Cyclin-Dependent Kinase Activity during Embryonic Stem Cell 
Differentiation." Molecular biology of the cell 16.4 (2005): 2018-27. 
 
Xia, X., and S. C. Zhang. "Genetic Modification of Human Embryonic Stem Cells." 
Biotechnology & genetic engineering reviews 24 (2007): 297-309. 
 
Xu, B., K. Zhang, and Y. Huang. "Lin28 Modulates Cell Growth and Associates with a Subset of 
Cell Cycle Regulator mRNAs in Mouse Embryonic Stem Cells." RNA (New York, N.Y.) 15.3 
(2009): 357-61. 
 
Xu, N., et al. "MicroRNA-145 Regulates OCT4, SOX2, and KLF4 and Represses Pluripotency 
in Human Embryonic Stem Cells." Cell 137.4 (2009): 647-58. 
 
Yamakuchi, M., M. Ferlito, and C. J. Lowenstein. "MiR-34a Repression of SIRT1 Regulates 
Apoptosis." Proceedings of the National Academy of Sciences of the United States of America 
105.36 (2008): 13421-6. 
 
Yang, D., et al. "Human Embryonic Stem Cell-Derived Dopaminergic Neurons Reverse 
Functional Deficit in Parkinsonian Rats." Stem cells (Dayton, Ohio) 26.1 (2008): 55-63. 
 
Yu, J., et al. "Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells." Science 
(New York, N.Y.) 318.5858 (2007): 1917-20. 
 
 105 
 
Zhang, X., et al. "A Role for NANOG in G1 to S Transition in Human Embryonic Stem Cells 
through Direct Binding of CDK6 and CDC25A." The Journal of cell biology 184.1 (2009): 67-
82. 
 
Zhang, Y., Y. Xiong, and W. G. Yarbrough. "ARF Promotes MDM2 Degradation and Stabilizes 
p53: ARF-INK4a Locus Deletion Impairs both the Rb and p53 Tumor Suppression Pathways." 
Cell 92.6 (1998): 725-34. 
 
Zhao, Y., et al. "Two Supporting Factors Greatly Improve the Efficiency of Human iPSC 
Generation." Cell stem cell 3.5 (2008): 475-9. 
 
Zhou, J., & Prives, C. (2003). Replication of damaged DNA in vitro is blocked by p53. Nucleic 
Acids Research, 31(14), 3881-3892. 
 
Zolochevska, O., and M. L. Figueiredo. "Cell Cycle Regulator cdk2ap1 Inhibits Prostate Cancer 
Cell Growth and Modifies Androgen-Responsive Pathway Function." The Prostate 69.14 (2009): 
1586-97. 
 
  
 106 
 
 
 
 
APPENDIX 
 
 
 
Bromodeoxyuridine (BrdU) Proliferation Assay 
1. Seed cells to be assayed in the appropriate density in 4-chamber slides and incubated in 
37 degrees, 5% CO2 incubator overnight. 
2. The next day, BrdU (Sigma, Cat# B9285-250G) is added to the medium in 20 μg/ml final 
concentration. Put the slides back in the incubator for 4-6 hrs.  
3. After 4-6 hrs, cells are washed with ice cold PBS buffer and then fixed in 100% methanol 
in -20C for 15 min.  
4. After fixing, the cells were washed in cold PBS and permeabilized by adding 0.2% 
Triton-X for 15 min at room temperature.  
5. For DNA denaturation (antigen retrieval), cells are treated with 2N HCL solution for 45 
min at room temperature.  
6. To neutralize the HCL, Borate buffer is added for 6 min and washed. This should be done 
twice to insure neutralization of HCL.  
7. After that blocking using 3% goat serum is performed for 45 min at room temperature.  
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8. Remove blocking and add primary BrdU antibody (Abcam, Cat# 1893) at (1:500 
dilution) and incubate overnight at 4C.  
9. The next day, wash cells three times with PBS buffer with 5 min incubation for every 
wash.  
10. Secondary antibody (Goat anti-Rat, Alexa fluor 594, Cat# A-11007) is then added and 
incubated at room temperature for 1 hr.  
11. Cells were then washed with PBS and labeled with DAPI (1:10,00 dilution in deionized 
water) 
12. To calculate the percentage of BrdU positive cells, view slides at 20X magnification and 
Select random fields. Determine the total number of cells in each field by counting nuclei 
(DAPI). Determine the number of BrdU positive cells in the field. Calculate the 
percentage by dividing the number of BrdU positive cells by the total number of cells in 
the field x 100. 
 
 Immunoblotting (Western Blot) 
 
1. Sample preparation 
 Cells must be confluent and ready to be harvested from a 60mm cell culture plate.  
 Use the total protein extraction kit which has 50x Protease inhibitor cocktail + 
TM lysis buffer (with NP40). Make 1x Protease inhibitor by diluting it from 50x 
using lysis buffer. 
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 Wash the cell plate with PBS after aspirating the media out. Be careful not to 
leave any traces of media in the plate as this will obstruct viewing the protein of 
interest on SDS PAGE later on. 
 Use ice cold PBS and cold tubes for the rest of the sample preparation. 
 Trypsinize the cells and spin them down. 
 Wash the cell pellet with PBS. 
 Add 100 µl of lysis buffer to 1 million cells. 
 Pipette it up and down. 
 Tape the tubes down to a vortex and keep it on constant agitation at 4°C for 30 
minutes. 
 Centrifuge at 13000 g at 4°C for 15-20 minutes. 
 Collect the supernatant and dump the pellet. The supernatant is the protein. 
2. Protein concentration: BSA assay 
 Dye reagent (5x) 
 BSA lyophilized powder 
 Add 20 ml water to do the BSA powder and mix it to get a 1.44 mg/ml protein 
solution. 
 Make three dilutions of protein solution (0.2 mg/ml, 0.4 mg/ml, 0.8 mg/ml). 
0.8 mg/ml: 1.44 mg – 1ml 
        0.8 mg – 0.8/1.44 = 0.556 ml 
         Add 0.444 ml dd H2O 
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         1ml of 0.8 mg/ml solution 
0.4 mg/ml: Take 0.5 ml of 0.8 mg/ml and add 0.5 ml of dd H2O to get 1 ml of 0.4 
mg/ml solution. 
0.2 mg/ml: Make 1ml of protein solution in the same way as above. 
 Dye reagent: 1 part of 5x dye + 4 parts water = 25 ml dye (1x) 
Pour the dye reagent through a Whatman filter paper. 
 Take 20 µl of protein (standards/sample) for 1ml of dye reagent and vortex it 
properly and incubate it for 5min at room temperature. 
 Perform spectrophotometric analysis at 595nm to get the OD values. 
 Only 30 µg of protein per well in gel. Do the calculations and take the required 
amount of protein sample and make up the volume to 30 µl using laemmli buffer 
(1:1 or 1:2). 
 Before using the laemmli buffer, it is required to add β-mercaptoethanol to the 
laemmli buffer. 
 Add 50 µl β-mercaptoethanol to 950 µl Laemmli buffer and mix it well.   
 Add 1:1 ratio of Laemmli buffer to protein sample. 
 Boil water on a burner, parafilm-seal the lids of the eppendorf tubes that contain 
sample and place the samples in boiling water for around 10 minutes. 
 Spin them down to the bottom of the tube. 
3. Running SDS PAGE 
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 Making running buffer: Take 900ml ddH2O in a glass bottle and add 100ml of 
Tris-Glycine-SDS and mix it well. 
 Once the samples and buffers are ready, take them near the running apparatus. 
 Get the gel ready from 4°C and take the tape off the bottom of the gel. 
 Place it carefully in the gel holder and make sure to place the gel in a way that the 
wells are facing inside. Balance the other side using another gel if you are running 
two gels at the same time or use a dam to seal the other end.  
 Pour running buffer into the gel holder to check if it is sealed well.  
 Once it is established that there are no leaks, go ahead and take the comb out of 
the wells and saturate it with running buffer. 
 Load ladder and samples carefully into the respective wells without releasing air 
bubbles into the well from the pipette. 
 Run at 20mA for around 45min or till the protein reaches the bottom of the gel. 
Be careful not to let the protein run out from the bottom of the gel. If the gel has 
run well, the ladder is well separated. 
4. Transfer onto nitrocellulose membrane 
 Preparation: While the SDS PAGE is still running, get the transfer buffer ready 
and store it at 4°C. 
o Take 700 ml water, 100 ml tris-glycine, 200 ml methanol and mix it well.  
o Take ice in white ice-holder and fill it with a little water and keep it at -
20°C until use.  
o Cut the required size of the nitrocellulose and be careful not to touch 
without gloves and hold it using forceps. Place it in some transfer buffer. 
 111 
 
o Wet the sponges and filter paper in the transfer buffer as well. 
 
 Once the gel is run, carefully break open the gel case without breaking the gel. 
 Place the nitrocellulose on gel supported by a filter paper. 
 Let the gel come onto the membrane and then place another filter paper on gel. 
 Press them smoothly and now place sponges on either side and roll a Pasteur 
pipette on this sandwich tightly to get rid of bubbles. (IMPORTANT) 
 Do not forget the gel side and the membrane side. 
 Black side: Gel 
Clear side: Nitrocellulose membrane 
 Clear side should go next to red and black side onto black and back goes back. 
Place the other sandwich with another set of gel-membrane or plain sponges. 
 Place the ice pack in the apparatus and place the whole apparatus in a trough 
containing ice. 
 Now pour the cold transfer buffer into the apparatus and run it at 90V for around 
1 hour 15 min-30min.  
 You know the transfer has begun once you notice bubbles rising up from the 
bottom. 
 The transfer is successful when the ladder is perfectly visible on the nitrocellulose 
membrane. 
5. Blocking and washes: 
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 Use 3% block solution or make 5% block using nonfat casein powder in TBS-
Tween solution  
 TBS-Tween: 900ml water, 100ml TBS, 1ml Tween-20 
 Do a 10 min wash with TBS-Tween. 
6. Primary and Secondary Antibodies: 
 Make the primary antibody solution in 0.1% TBS-Tween solution (15ml). It can 
be reused when stored at 4°C. 
 Add it to the washed membrane and leave it overnight at 4°C with constant 
agitation or upto 2 hrs at room temperature with stirring.  
 Do 3x 10 min washes with TBS-Tween. 
 Make secondary antibody in TBS-Tween (10ml). 
 Add it onto membrane and leave it on stirring for 1 hour. 
 Do not reuse the secondary antibody solution. 
Do 3x 10 min washes with TBS-Tween and detect using the Odyssey Infrared Imaging System 
(Li-Cor Biosciences, NE). 
 
CDK2AP1 knockdown 
CDK2AP1 specific shRNAs were purchased from OpenBiosystems, PA and SIGMA, MO. 
ShRNAs were received in glycerol stocks. 
 Use a sterile pipette tip to inoculate a small amount of the glycerol stock of the shRNA 
and streak on an agar plate that has the appropriate antibiotic. 
 Place the agar plates upside down in an incubator at 37 C overnight. 
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 The following day, observe the plates for resistant colonies.  
 Using a sterile pipette tip pick well isolated colonies and insert it in a glass tube 
containing 3-5 mls of LB medium with appropriate antibiotic. 
 Place the tubes in the 37 incubator/shaker for 16-18 hrs in constant agitation at 280 rpm. 
 Dilute 0.5-2 mls of the liquid bacterial culture prepared in the previous step in 100 mls 
LB medium with the appropriate antibiotic and incubate at 37 C at constant 280 rpm 
agitate overnight. 
 The next day, collect liquid culture and extract plasmid using the Qiagen Maxi Prep kit 
(Cat number 12963) by following the manufacturer’s directions. 
 Using the spectrophotometer, determine the plasmid concentration. 
 To generate lentiviruses containing shRNA: 
- Seed HEK293 cells onto 10 cm cell culture plate. 
- When cells reach ~ 70% confluency, transfect with 10 µg of the shRNA plasmid + 7.5 
µg packaging plasmid (psPAX2) (Addgene, MA) + 2.5 µg envelope plasmid (pMD.2) 
(Addgene, MA). Use Roche transfection reagent, X-tremeGENE.9. 
- 48 h later, collect supernatant which contains the viral particles and filter it using a 0.45 
µm filters. 
- Concentrate the viral supernatant using the Lenti-X concentrator (Clontech, CA) by 
following the manufacture’s protocol. 
- Resuspend the  viral particles in 500 µl Opti-MEM and aliquot in 50 µl and store the 
tubes at -80 C for later use. 
 To knockdown CDK2AP1, seed around 100k cells per 35 mm dish (this density is 
optimized for human embryonic stem cells (hESCs) and primary human fibroblasts 
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(HDFs). Adjustments may need to be made depending on the cell line you are 
transducing). 
 Add ~25 µl of virus per 35 mm plate with the addition of Polybrene (for hESCs and 
HDFs use 6 µg/ml) (Santa Cruz Biotech, CA).  
 The next day, remove transduction medium and add growth medium. 
 When cell become confluent, passage the cells 1:2 or 1:3 to increase the number of 
transduced cells.  
 The next day, add Puromycin to select the successfully transduced cells. (use 3 µg/ml for 
HDFs and 0.5-1 µg/ml for hESCs). 
 Resistant cells can be collected following ~5 days of antibiotic treatment. 
 Determine the degree of knockdown using qPCR or Western Blot. 
 
Cell Cycle Analysis by Propidium Iodide (PI) Staining 
 To prepare PI staining solution stock: 
- Add 100 ml of Tris Buffered Saline (pH = 7.6) 
- Add 1 mg of Ribonuclease A (Type-II; 70 U/mg) (Sigma #R-5000) 
- Weigh 7.5 mg of Propidium Iodide (Sigma #P-4170) and add it to the solution 
- Add 0.1 ml of IGEPAL CA-630 (Sigma #I-8896).  
- Cover the container with foil and store at 4 C 
 Place 500k -106 cells in 12 x 75 mm tube  
 Centrifuge the cells at 250g for 5 minutes.  
 Discard supernatant and resuspend cells in 0.5-1 ml of the prepared PI solution.  
 Incubate at 37 C for 45 min  
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 Before analysis, Samples need to be filtered through a 30μm mesh to eliminate clumps. 
 Analyze on Accuri flow cytometer at low flow rate (~150 cells/second or less). 
 Threshold debris using Forward Scatter, then gate using PI-area vs. PI-height to eliminate  
doublets. Viable nuclei will have some Forward Scatter and little 90 degree –Scatter.  
 Analyze cells using PI-area.  
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